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 Abstract 
Activation of innate immunity through Toll-like receptor (TLR) signaling can also 
enhance antigen-specific adaptive immunity. TLR9 is an endosomal receptor for unmethylated 
bacterial and viral cytosine-phosphate-guanine DNA (CpG-DNA). West Nile virus (WNV) 
infection may result in meningitis and encephalitis in humans and horses, especially aged and 
immunocompromised individuals. Using flow cytometric analyses and quantitative reverse 
transcriptase-polymerase chain reaction (RT-PCR), we investigated equine cell-mediated 
immunity (CMI) to an inactivated West Nile virus vaccine in healthy yearling and adult horses.  
We also studied the potential of enhancing equine adaptive immunity to viruses and other 
pathogens by activation of innate immunity though TLR9 signaling pathway. We found 
vaccination with inactivated WNV vaccine induced strong WNV-specific T helper type 1 (Th1) 
and Th2 CMI with a Th1 bias, also effectively induced WNV-specific CTLs in yearling horses. 
In adult horses, the pre-existing Th1 CMI bias against WNV was enhanced following booster 
vaccination with inactivated WNV vaccine. Molecular characterization and flow cytometric 
analysis of TLR9 expression using a cross-reactive TLR9 mAb identified high constitutive 
expression of equine TLR9 in neutrophils (PMNs), CD4+ and CD8+ T cells and other leukocytes. 
Conservation of equine TLR9 and a high expression profile among leukocytes suggests that 
equine TLR9 is a frequent target for unmethylated CpG-DNA, an essential mechanism for the 
activation of innate immunity. Unmethylated CpG-DNA can significantly activate equine PMNs. 
It also induces expression of interferon (IFN)-α, IFN-β, IFN-γ, and interleukin (IL)-12p35 in 
PBMCs, as well as IFN-α and IFN-γ in monocyte-derived DCs. Enhanced expression of IFNs in 
immune cells by CpG-DNA is not only crucial for host viral clearance, but also important in 
mediating host immune responses due to IFNs’ anti-inflammatory effects. Compared to the 
relatively weaker activation of equine innate immunity by inactivated WNV, the tested CpG-
DNA species showed potential as vaccine adjuvants for enhancement of CTLs and Th1 CMI 
against intracellular pathogens, characterized by significant induction of type I IFNs and Th1-
specific cytokines such as IL-12p35 and IFN-γ. These data provide a basis for further 
investigation of these CpG-DNA species as potentially effective vaccine adjuvants in horses.
 
  
EQUINE INNATE AND ADAPTIVE IMMUNITY TO VIRAL INFECTIONS 
 
 
 
by 
 
 
 
YUWEN ZHANG 
 
 
 
B.S., Huazhong Agricultural University, 1991 
M.S., Chinese Academy of Agricultural Sciences, 1994 
M.S., Kansas State University, 2002 
 
 
 
A DISSERTATION 
 
 
submitted in partial fulfillment of the requirements for the degree 
 
 
 DOCTOR OF PHILOSOPHY 
 
 
Department of Anatomy & Physiology 
College of Veterinary Medicine 
 
 
 
 
KANSAS STATE UNIVERSITY 
Manhattan, Kansas 
 
 
2008 
 
Approved by: 
 
Major Professor 
Dr. Elizabeth G. Davis 
 
 Abstract 
Activation of innate immunity through Toll-like receptor (TLR) signaling can also 
enhance antigen-specific adaptive immunity. TLR9 is an endosomal receptor for unmethylated 
bacterial and viral cytosine-phosphate-guanine DNA (CpG-DNA). West Nile virus (WNV) 
infection may result in meningitis and encephalitis in humans and horses, especially aged and 
immunocompromised individuals. Using flow cytometric analyses and quantitative reverse 
transcriptase-polymerase chain reaction (RT-PCR), we investigated equine cell-mediated 
immunity (CMI) to an inactivated West Nile virus vaccine in healthy yearling and adult horses.  
We also studied the potential of enhancing equine adaptive immunity to viruses and other 
pathogens by activation of innate immunity though TLR9 signaling pathway. We found 
vaccination with inactivated WNV vaccine induced strong WNV-specific T helper type 1 (Th1) 
and Th2 CMI with a Th1 bias, also effectively induced WNV-specific CTLs in yearling horses. 
In adult horses, the pre-existing Th1 CMI bias against WNV was enhanced following booster 
vaccination with inactivated WNV vaccine. Molecular characterization and flow cytometric 
analysis of TLR9 expression using a cross-reactive TLR9 mAb identified high constitutive 
expression of equine TLR9 in neutrophils (PMNs), CD4+ and CD8+ T cells and other leukocytes. 
Conservation of equine TLR9 and a high expression profile among leukocytes suggests that 
equine TLR9 is a frequent target for unmethylated CpG-DNA, an essential mechanism for the 
activation of innate immunity. Unmethylated CpG-DNA can significantly activate equine PMNs. 
It also induces expression of interferon (IFN)-α, IFN-β, IFN-γ, and interleukin (IL)-12p35 in 
PBMCs, as well as IFN-α and IFN-γ in monocyte-derived DCs. Enhanced expression of IFNs in 
immune cells by CpG-DNA is not only crucial for host viral clearance, but also important in 
mediating host immune responses due to IFNs’ anti-inflammatory effects. Compared to the 
relatively weaker activation of equine innate immunity by inactivated WNV, the tested CpG-
DNA species showed potential as vaccine adjuvants for enhancement of CTLs and Th1 CMI 
against intracellular pathogens, characterized by significant induction of type I IFNs and Th1-
specific cytokines such as IL-12p35 and IFN-γ. These data provide a basis for further 
investigation of these CpG-DNA species as potentially effective vaccine adjuvants in horses. 
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CHAPTER 1 - Equine cell-mediated immune response to an 
inactivated West Nile virus vaccine 
 
 
Abstract 
 
West Nile virus (WNV) (Flavivirus: Flaviviridae) infection may result in meningitis 
and/or encephalitis in humans and horses, especially aged and immunosuppressed individuals. 
Immunization with West Nile Innovator®, an inactivated WNV vaccine, against WNV infection 
in equine with recommended doses has been very effective. However, except for humoral 
immunity, equine cell-mediated immunity (CMI) against WNV after vaccination with this 
inactivated WNV vaccine has not been unraveled. Compared to adult horses, juvenile horses 
may be defective in generating effective T helper (Th) type 1 immunity and susceptible to WNV 
infection. Utilizing flow cytometry, quantitative RT-PCR and carboxyfluorescein succinimidyl 
ester (CFSE)-based cell proliferation, we investigated CMI to vaccination with West Nile 
Innovator® in healthy yearling and adult horses. We found, in addition to strong WNV-specific 
humoral immune response as reported and in our study, the inactivated WNV vaccine can induce 
strong WNV-specific Th1 (IFN-γ secreting CD4 T cells) and Th2 (IL-4 secreting CD4 T cells) 
CMI with a Th1 bias, and also induce WNV-specific IFN-γ secreting CD8 T cells in yearling 
horses. In adult horses, the preexisted Th1 CMI bias against WNV can be enhanced and become 
more pronounced by booster vaccination with the inactivated WNV vaccine. 
 
Keywords: Equine, West Nile virus, cell-mediated immunity, inactivated WNV vaccine 
 
1. Introduction 
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WNV is a positive sense, approximately 11 kb single-stranded RNA arbovirus. Its 
genome encodes capsid (C), envelope (E), premembrane/membrane (prM/M), and 7 
nonstructural (NS) proteins. This endemic arbovirus is mainly transmitted by Culex mosquitoes 
from birds, a major WNV reservoir. WNV infection can cause meningitis, encephalitis and 
encephalomyelitis, in which mortality can be as high as 10–15% in humans and 28-45% in 
horses (Brinton, 2002; Hayes et al., 2005; van der Meulen et al., 2005; Davis et al., 2006; Hayes 
and Gubler, 2006; Sejvar and Marfin, 2006; Kramer et al., 2008). 
Studies of WNV disease using the murine model have been well-documented in recent 
years and clearly demonstrate that both innate immunity, including interferons (IFN-α, IFN-β 
and IFN-γ), γδT cells, and complement, and adaptive immunity, including cytotoxic T 
lymphocytes (CTLs) and Th1 cell-mediated immunity (CMI), and humoral immunity, are 
essential for the host to clear WNV, especially in the central nervous system (CNS) (Samuel and 
Diamond, 2006). In humans, the antigenic WNV viral epitopes for antibody (Ab) neutralization 
and presentation by major histocompatibility complex (MHC) classes I and II map to the C, M, E 
and all NS proteins (Sanchez et al., 2007; Lanteri et al., 2008; McMurtrey et al., 2008; Parsons et 
al., 2008), even though with varying degree of immune responses to epitopes among individuals. 
The optimal method for disease prevention against WNV is vaccination (Salazar et al., 2004; 
Schuler et al., 2004; Ward et al., 2004; Dauphin and Zientara, 2007; Gardner et al., 2007; Long 
et al., 2007; Chang et al., 2008), with either partial or all the viral antigens (whole attenuated or 
inactivated viruses) for induction of community immunity or herd immunity. 
Currently there are four licensed WNV vaccines available for equines: West Nile-
Innovator® and West Nile-Innovator DNA® (Fort Dodge Animal Health, Division of Wyeth, Fort 
Dodge, IA), Prevenile® (Intervet, De Soto, KS, equivalent to Chimerivax-WN®, Acambis, 
Cambridge, MA), and Recombitek® equine WNV vaccine (Merial Limited, Athens, GA) 
(Meeusen et al., 2007; Kramer et al., 2008). West Nile-Innovator® is formalin-inactivated WNV 
vaccine with the adjuvant Metastim® (Fort Dodge Animal Health). West Nile-Innovator DNA® 
was the first licensed DNA vaccine (Davis et al., 2001). Prevenile® is a live attenuated chimeric 
WNV/YFV (yellow fever virus) vaccine without adjuvant (Long et al., 2007; Seino et al., 2007). 
Recombitek® is a recombinant canarypox virus vaccine with adjuvant (Minke et al., 2004; Siger 
et al., 2004; El Garch et al., 2008). The last three vaccines all encode the E and preM proteins as 
antigens. 
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West Nile-Innovator® was the first licensed WNV vaccine and thus mostly tested in small 
and large scale trials for safety and vaccine efficacy (Ng et al., 2003; Vest et al., 2004; Epp et al., 
2005). This killed WNV vaccine has demonstrated an efficacy of about 95% against WNV 
disease (Ng et al., 2003; Epp et al., 2005) in small (20 horses) and large scale (875 horses) 
studies. Although elevated levels of serum neutralizing antibodies due to vaccination likely play 
an important role in clearing WNV in horses, whether vaccination with this inactivated WNV 
can induce CMI against WNV has not been reported, especially in yearling horses. Here we 
evaluated the CMI against WNV in healthy yearling and adult horses after vaccination with West 
Nile-Innovator® and found that this killed WNV vaccine stimulated robust antigen-specific Th1 
CMI (IFN-γ secreting CD4 T cells) as well as IFN-γ secreting CD8 T cells against WNV in 
yearling horses. Such a Th1 CMI immune response was more pronounced in adult horses. 
 
 
2. Materials and Methods 
 
2.1. Animals, vaccination schedule and blood sampling 
 
All animal protocols were approved by the Institutional Animal Care and Use Committee 
at Kansas State University. There were two treatment groups of healthy yearling horses: saline 
placebo and vaccination (West Nile Innovator®), with 6 horses per group. Yearling horses were 
vaccinated three times with an interval of three weeks. Peripheral blood samples (heparinzed) 
were collected by jugular venipuncture for evaluating immune responses to vaccination at 
baseline (0 day), 1, 2, 3, 4, 5, 8, 10, 12, 16, 20, 24, 28 and 32 weeks.  Serum samples from these 
yearling horses were tested for WNV infection by IgM capture ELISA and plaque reduction 
neutralization test (PRNT) at the National Veterinary Services Laboratories (NVSL, Ames, 
Iowa) as well as ELISA of all Ab classes and IgG subclasses specific to the WNV preM and E 
proteins in our lab to monitor humoral immunity and natural exposure to WNV throughout the 
experiment. 
Six healthy adult horses (13 to 21 years old) that were previously vaccinated against 
WNV once or twice annually were utilized to characterize the CMI against WNV in adults after 
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vaccination with the killed WNV vaccine. Blood samples were collected before the initial annual 
booster vaccination against WNV, then 1 and 2 weeks after vaccination. 
 
2.2. Cell Culture 
 
Equine peripheral blood mononuclear cells (PBMCs) were isolated by density gradient 
and cultured as reported (Zhang et al., 2008). Cultured PBMCs were treated with or without 
purified WNV antigen (pre-membrane + envelope proteins, 20 µg/ml) for 3-5 days. Then cells 
were treated with GolgiplugTM (protein transport inhibitor Brefeldin A, BD Sciences, San Jose, 
CA) for 12 hrs before harvest for cytokine staining. 
Some PMBCs were stained with carboxyfluorescein succinimidyl ester (CFSE) for 
tracking WNV-specific cell proliferation with the following modified method (Lyons and Parish, 
1994; Hodgkin et al., 1996). Briefly, cells (2 x 106/ ml) were stained with 1µM CFSE at room 
temperature in the dark for 15 min. The staining was terminated by adding 4-5 ml of equine 
serum and RPMI 1640 (Hyclone, Logan, UT) to bring the volume up to 25 ml in a 50 ml tube. 
CFSE-stained PBMCs were centrifuged for 10 min at 400 g at room temperature. After 
decanting the supernatant, the cells were resuspended for culture. After culturing with or without 
purified WNV antigens for 5 days, cells were then counted and harvested for surface 
immunophenotyping by flow cytometry. 
 
2.3. Abs and flow cytometry 
 
Primary mouse anti-equine CD4 (HB61A), CD8 (HT14A) and MHC classes I (H58A) 
and II (H42A) mAbs were purchased from VMRD (Pullman, WA). Secondary goat anti-mouse 
Abs, APC-conjugated, were from Invitrogen (Carlsbad, CA). The cross-reactive mouse anti-
bovine IFN-γ (CC302, AbD Serotec, Raleigh, NC) (Pedersen et al., 2002; Paillot et al., 2005) 
and IL-4 (CC303, AbD Serotec) (Pedersen et al., 2002) mAbs were from AbD Serotec and their 
isotype control mAbs (clone MOPC-21, FITC or PE conjugated) from BD Sciences Pharmingen. 
The cross-reactivity of mouse anti-bovine IL-4 with equine IL-4 was confirmed with horse 
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PBMCs treated with PHA (5 ug/1x 106 cells/ml) or PMA plus ionomycin as reported (Wagner et 
al., 2006). Similar results were obtained (data not shown). 
For all animals, complete blood counts (CBC) were performed and leukocytes were 
immuno-phenotyped on CD4, CD8, MHC classes I and II by flow cytometry to ensure these 
animals had no immune deficiency (Davis et al., 2002). For investigation of CMI, cultured 
PBMCs were first surface-stained with CD4 and CD8 mAbs, then fixed and permeablized for 
intracellular IFN-γ and IL-4 mAb staining, following the protocol with the FIX & PERM kit 
(Invitrogen). For cell proliferation, CFSE stained cells were surface-stained with Abs against 
CD4, CD8, MHC class I and II for flow cytometric analysis as reported (Zhang et al., 2008). 
Only viable cells (based on propidium iodide staining of separate samples) were gated for flow 
cytometric analysis. 
Flow cytometric two-color dot plot analysis was performed using CellQuest (BD 
Sciences) or Winlist 6.0 software (Verity Software House, Topsham, ME). 
 
2.4. Quantitative RT-PCR 
 
Quantitative RT-PCR was performed on DNase I-digested total RNA samples from 
individual animals using the QuantiFast SYBR Green RT-PCR Kit (Qiagen Inc, Valencia, CA) 
in a Bio-Rad iCycler iQ Real Time PCR System (Bio-Rad, Hercules, CA). 
Quantitative RT-PCR for 18S rRNA (as the internal control), IFN-γ and IL-4 was 
performed in 15-ul reactions with 15 ng total RNA and gene-specific primers (Table 1.1). The 
specificity of every primer pair was confirmed by sequencing amplicon if unique product was 
amplified based on electrophoresis in 1-2% agarose gel, as well as melting-curve analysis in real 
time RT-PCR. Negative controls without total RNA were included for each run of real time RT-
PCR. The PCR amplification efficiency of each reaction was estimated by linear regression, in 
which 3 to 6 points covering the Ct value were utilized based on the highest correlation 
coefficiency (Ramakers et al., 2003). The averaged PCR efficiency for each gene was utilized for 
computing relative gene expression (Pfaffl, 2001; Cikos et al., 2007). IFN-γ and IL-4 data were 
normalized to 18S rRNA. 
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2.5. Data Analyses 
 
Prior to vaccination, all yearling horses except one were negative of WNV IgM capture 
ELISA and PRNT as well as no difference between the two groups in WNV-specific IgM, IgA, 
IgG(T), IgGa, IgGb and IgGc, and no recalled WNV-specific CMI was detected in these animals. 
The PRNT for WNV for one of the vaccinated horses was found positive (titer >1:10), so this 
horse was considered as a positive control and excluded for all data analysis. After 10 weeks post 
primary vaccination, three of the yearling control horses were found PRNT positive for WNV, 
thus no data after this point were shown even though random natural exposure to WNV infection 
did not affect the difference in immunity to WNV between vaccinated and control (placebo) 
animals. 
Based upon the flow cytometric data from two-color contour dot plots in either CellQuest 
(BD Sciences) or Winlist 6.0 (Verity Software House), the WNV antigen specific immune 
response was computed as the difference between WNV stimulation and culture media. One way 
analysis of variance or Kruskal-Wallis one way analysis of variance on ranks in SigmaStat 3.5 
was performed for all data analyses. Paired t-test in SigmaStat 3.5 was performed for analyzing 
the relative IFN-γ and IL-4 expression in PBMCs. p < 0.05 is considered statistically significant. 
 
 
3. Results 
 
3.1. WNV-specific CMI 
  
To investigate the CMI elicited by vaccination with killed WNV vaccine in horses, 
purified PBMCs were cultured with and without WNV antigen stimulation. We measured IFN-γ 
(Fig. 1.1. A & B) and IL-4 production by CD4 T cells, and IFN-γ production by CD8 T cells by 
flow cytometry. Then we evaluated the WNV-specific IFN-γ and IL-4 production by CD4 T 
cells, and IFN-γ production by CD8 T cells, respectively as the difference between WNV 
antigen-stimulation and media alone. 
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 3.1.1. WNV-specific Th1 CMI 
  
IFN-γ production by CD4 T cells is critical for the clearance of viral and other 
intracellular pathogens. Thus, the induction of antigen-specific Th1 CMI by vaccination is a 
crucial parameter for evaluating vaccine efficacy (Kaech et al., 2002; Lambert et al., 2005; Seder 
et al., 2008). Fig. 1.1A & B demonstrated our flow cytometric assay of WNV-specific IFN-γ 
production by CD4 T cells. Compared to control horses, which showed little WNV-specific IFN-
γ secreting CD4 T cells, vaccinated yearling horses consistently showed significantly higher 
frequency of WNV-specific IFN-γ secreting CD4 T cells since 14 days after primary vaccination. 
Such a Th1 CMI was enhanced by the first and second booster vaccinations. The dynamic trend 
in Th1 CMI response to vaccination during a series of time points varied considerably among 
animals (Fig. 1.1 C). Ten weeks after primary vaccination, this Th1 CMI decreased but 
maintained (data not shown). 
 
3.1.2. WNV-specific Th2 CMI 
  
The induction of antigen-specific IL-4 producing CD4 T cells is often observed after 
vaccination (Lambert et al., 2005), especially in youngsters because youngsters, particularly 
neonates, are limited in Th1 CMI and their immature CMI is Th2 biased (Adkins et al., 2004; 
Breathnach et al., 2006). Likewise for the killed WNV vaccine, control horses showed no 
recalled Th2 CMI response to vaccination, but vaccinated yearling horses consistently showed 
significantly higher frequency of WNV-specific IL-4 secreting CD4 T cells since 14 days after 
primary vaccination. Such a Th2 CMI was also enhanced by the first and second booster 
vaccinations (Fig. 1.2). Ten weeks after primary vaccination, this Th2 CMI decreased but was 
maintained significantly (data not shown). 
 
3.1.3. WNV-specific CD8 T cells 
  
Antigen-specific CTL (mainly of IFN-γ secreting CD8 T cells) activity also is critical for 
the clearance of viral and other intracellular pathogens (Kaech et al., 2002; Lambert et al., 2005; 
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Seder et al., 2008). Compared to control horses, vaccinated yearling horses showed significantly 
higher frequency of recalled WNV-specific CD8 T cells at 7 and 14 days after the first booster 
vaccination, but appeared not enhanced by the second booster vaccination (Fig. 1.3). Ten weeks 
after primary vaccination, this CTL activity still maintained (data not shown). The frequency of 
WNV-specific IFN-γ secreting CD8 T cells was much lower than that of WNV-specific IFN-γ 
secreting CD4 T cells. Similar results also were found in adult horses after booster vaccination 
with killed WNV vaccine (data not shown). 
 
3.1.4. WNV-specific Th1 vs Th2 CMI 
  
Th2 CMI might function antagonistically against Th1 CMI for young hosts to balance 
their immature adaptive immunity and prevent possible deleterious impacts from exuberant IFN-
γ producing CD4 T cells. The balance between Th1 and Th2 CMI might somehow indicate the 
efficacy of vaccination. We chose vaccinated healthy adult horses as positive controls for 
comparison of Th1 and Th2 CMI because their host immune responses to vaccination should be 
protective after long term immune selection through either vaccination and/or natural infection. 
Healthy yearling horses showed a Th1-biased CMI against WNV even though the Th2 CMI was 
also strong (Fig. 1.4A). Compared to the relative magnitudes of Th1 and Th2 CMI to killed 
WNV vaccine in yearlings, adult horses demonstrated a dominant Th1 CMI against WNV at 
baseline and boosted responses 1 and 2 weeks after the booster vaccination (Fig. 1.4B). 
 
3.1.5. Quantitative RT-PCR of IFN-γ and IL-4 expression 
  
To further confirm the WNV-specific induction of IFN-γ and IL-4 by T cells, using 
quantitative RT-PCR, we analyzed the relative expression of IFN-γ and IL-4 by PBMCs with and 
without WNV antigen stimulation at a few relatively comparable time points in yearling and 
adult horses: baseline, 2 weeks after the first booster vaccination for yearling horses, and 2 
weeks after the booster vaccination for adult horses. The adult horses demonstrated dramatic fold 
increase in WNV-specific IFN-γ production over IL-4 after WNV antigen stimulation in vitro, 
the yearling horses showed a balanced WNV-specific IFN-γ and IL-4 production (Fig. 1.5A). 
After in vitro WNV antigen stimulation, the ratio of IFN-γ to IL-4 expression by PBMCs from 
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yearling horses was about 40 fold lower in average than that from adult horses (Fig. 1.5B). These 
data supported the flow cytometric data of Th1 and Th2 CMI against WNV. 
 
3.2. WNV-specific cell proliferation 
  
CFSE-based cell proliferation is a widely-applied effective technique to evaluate antigen-
specific CMI by flow cytometry, in which CFSE is measured by FL1 height, the green channel 
detector (Lyons and Parish, 1994; Lyons, 2000). If immunological reagents available, multiple-
color flow cytometric analysis can be carried out to simultaneously characterize multiparameters 
of antigen-specific cell proliferation and its regulation (Krupnick et al., 2001; Hilchey and 
Bernstein, 2007). In our study, we mainly investigated the WNV-specific proliferation of CD4 
and CD8 T cells as well as their activation status based on MHC class II expression by flow 
cytometry. In panels A and B of Fig. 1.6, we demonstrated the flow cytometric assay of WNV-
specific CD4 T cell proliferation from a typical vaccinated yearling horse. Compared to control 
horses, vaccinated yearling horses consistently showed a significantly higher frequency of 
WNV-specific CD4 T cells proliferation 7 days after primary vaccination. Such a proliferating 
CMI, including both Th1 and Th2 CMI, was enhanced by the first and second booster 
vaccinations (Fig. 1.6C). Also, compared to controls, vaccinated yearling horses showed a 
significantly higher percentage of WNV-specific CD8 T cell proliferation 14 days after the first 
booster vaccination. Such a proliferating CD8 T cells was little enhanced by the second booster 
vaccinations (Fig. 1.6D), and vaccinated yearling horses consistently showed significantly higher 
frequency of MHC class II cell proliferation since 7 days after primary vaccination (Fig. 1.6E). 
The WNV-specific MHC class II cell proliferation appeared highly synchronous with the WNV-
specific proliferation of CD4 and CD8 T cells and was also enhanced by the first and second 
booster vaccinations because MHC class II expression on CD4 and CD8 T cells may be 
associated with all T cell activation (Lunn et al., 1993). Similar results were observed in adult 
horses regarding the WNV-specific proliferation of CD4 and CD8 T cells as well as their 
activation status based on MHC class II expression (data not shown). 
 
 
 9
4. Discussion 
  
Our study showed that vaccination with an inactivated WNV vaccine induced WNV 
antigen-specific, protective Th1 CMI (Fig. 1.1) as well as humoral immunity (antigen-specific 
IgA, IgG(T), IgGa, IgGb and IgGc, data not shown) in yearling horses and such adaptive CMI 
was enhanced by booster vaccination. Even though Th2 CMI against WNV was also induced by 
vaccination, Th1 CMI against WNV was dominant in yearling horses and shown to be more 
pronounced in adult horses. WNV-specific CD8 T cell response was also induced consistently 
and significantly after the first booster vaccination in yearling horses and this immune response 
was more pronounced in adult horses due to booster vaccination. Two of the vaccinated yearling 
horses ( H6 and H9 in Fig. 1.1, 1.2 & 1.6) showed relative weaker CMI, either Th1 or Th2, than 
the other three vaccinated yearling horses, however, they were still able to acquire equivalent 
WNV-specific Ab levels of IgA and all IgG subclasses as of other vaccinated ones (data not 
shown). 
We demonstrated that the CFSE-based WNV-specific CD4 and CD8 T cell proliferation 
as well as their corresponding activation status in terms of surface expression MHC class II in 
yearling horses after vaccination (Fig. 1.6). Similar results were also observed in vaccinated 
adult horses (data not shown). 
Because antigen-specific immune responses in healthy adults should be protective 
through immune selection by the host under pathogenic challenge during growth and 
development, thus their preexisted Th1 CMI is enhanced by booster vaccination and should be 
induced quickly for protection if natural WNV infection occurs. Whether such an effective 
WNV-specific Th1 CMI in healthy adult horses is due to natural WNV infection or vaccination 
does not compromise, but only confirms that WNV-specific protective Th1 CMI can be induced 
in yearling horses by vaccination with the killed WNV vaccine. 
In the recall assay of CMI, we used incomplete WNV antigens (just preM and E proteins) 
for in vitro PBMC stimulation (same antigens for ELISA). These two antigens may not stimulate 
maximal recall cellular response as measured from PBMCs. Two of the vaccinated horses that 
consistently showed low Th1 CMI response to WNV preM and E proteins may have stronger 
Th1 CMI response to the C and NS proteins. Flow cytometric analysis was very sensitive and 
showed a significant difference in CMI between control and vaccinated yearling horses (Fig. 1.1, 
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1.2 & 1.6). These data were indirectly confirmed by our quantitative RT-PCR assay of IFN-γ and 
IL-4 expression in T cells after stimulation with WNV antigens (Fig. 1.5).  
An issue for the killed WNV vaccine is the typical relatively weaker CD8 T cells recall 
response in comparison with Th1 CMI (Lambert et al., 2005), as shown in yearling horses (Fig. 
1.1, 1.3 & 1.6) as well as in adult horses (data not shown). Also, the function of high level of 
WNV-specific IL-4 secreted by CD4 T cells in yearling horses after vaccination with the killed 
WNV vaccine is unknown. Such IL-4 production could contribute to the production of non-
opsonizing Abs, or the regulation of IFN-γ secreting CD4 T cells (Kaech et al., 2002). 
Many reports have shown the efficacy of killed WNV vaccine with recommended doses 
(Ng et al., 2003; Schuler et al., 2004; Ward et al., 2004; Davidson et al., 2005; Epp et al., 2005; 
Seino et al., 2007). One of these reports suggested that the immunogenicity of killed WNV 
vaccine might be weak in some horses based on the low titers (≤1:10 ) of WNV plaque reduction 
neutralization test (PRNT) (Davidson et al., 2005) at 4 to 6 weeks after vaccination in 
comparison with naturally infected horses at 4 to 6 weeks after disease onset. Since there was no 
challenge study for these vaccinated horses, such lower serum Ab titers against WNV in some 
vaccinated horses can also be interpreted that these horses cleared WNV more effectively and 
quickly, possibly with their more efficient innate immunity and/or WNV-specific adaptive 
immunity (CMI and Abs). 
Prevenile® and Recombitek® vaccines have also been showing good efficacy against 
WNV infection in horses (Minke et al., 2004; Siger et al., 2004; Long et al., 2007; Seino et al., 
2007; El Garch et al., 2008). However, horses vaccinated once with Prevenile® or twice with 
Recombiteck® only showed less than 1/44 or 1/8 of WNV neutralizing Ab level in horses 
vaccinated twice with West Nile-Innvator® before WNV challenge (Seino et al., 2007). This 
explains why Prevenile® or Chimerivax-WN® showed less vaccine efficacy against WNV 
infection than what is claimed (95%) (Long et al., 2007). The low neutralizing Ab level induced 
by Recombitek® is possibly due to strong host humoral response to the canarypox virus vector, 
thus little booster effect was found in WNV-specific Th1 CMI and humoral immunity (El Garch 
et al., 2008). In comparison to Prevenile® and Recombitek® vaccines, WNV antigens in killed 
WNV vaccine are more heterogenous, in which all the NS proteins are included as targets of 
CMI and humoral immunity (Sanchez et al., 2007; McMurtrey et al., 2008; Parsons et al., 2008). 
This may explain why West Nile Innovator® is better at the induction of WNV-specific humoral 
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immunity than Prevenile® and Recombitek® vaccines (Balasuriya et al., 2006; Seino et al., 2007) 
as well as showing clearer consistent induction of Th1 CMI and CTLs (Fig. 1.1, 1.3 & 1.6), even 
though this vaccine elicited slightly more clinical signs like swelling in the injection sites than 
the chimeric WNV vaccines (Ng et al., 2003; Seino et al., 2007). However, it is impossible for 
Prevenile® and Recombitek® to induce immune responses to the WNV NS proteins in animals 
simply because these two vaccines do not encode these NS proteins. Compared to chimeric live 
attenuated WNV vaccines, vaccines of killed WNV or purified WNV antigens may have more 
room for improvement of WNV-specific CTL and humoral responses with the help of effective 
adjuvants and vaccination strategy that can mimic natural viral infections (Zinkernagel and 
Hengartner, 2001; Davidson et al., 2005; Johansen et al., 2008; Lanteri et al., 2008), yet more 
researches still need to be done. 
In conclusion, in addition to strong WNV-specific humoral immune response as reported 
and in our study, the killed WNV vaccine can induce strong WNV-specific Th1 and Th2 CMI 
with a Th1 bias, and also induce WNV-specific CTLs in yearling horses. In adult horses, the 
preexisted Th1 CMI bias against WNV is more pronounced and can be enhanced by booster 
vaccination with the killed WNV vaccine. 
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Table 1.1. Primers for real time RT-PCR 
Gene Primer Sequence (5’ → 3’) Amplicon 
Length (bp) 
Genbank 
accession No. 
18S rRNA Forward ATGCGGCGGCGTTATTCC 204 AJ311673 
  Reverse GCTATCAATCTGTCAATCCTGTCC     
IFN-γ Forward GCCAAATCGTCTCCTTCTACTTC 260 D28520 
  Reverse CTGACTCCTCTTCCGCTTCC     
IL-4 Forward GAACAACCTCACAGATGGAAAG 238 AF305617 
  Reverse GCTCTTCTTGGCTTCATTCAC     
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Fig. 1.1. Vaccination with an inactivated WNV vaccine elicited effective Th1 CMI in 
yearling horses. Flow cytometric assay of WNV-specific Th1 CMI from a typical vaccinated 
horse was shown in panels A and B, all samples were gated on the viable cells that were 
identified by propidium iodide staining. (A) The IFN-γ secreting CD4 T cells cultured without 
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purified WNV antigens. (B) The IFN-γ secreting CD4 T cells cultured with purified WNV 
antigens (20 ug preM+ E proteins/ml). Brefeldin A was added to cells and incubated for 12 hr 
after all cells were cultured for 4 days. Then cells were harvested and stained for surface antigens 
and intracellular cytokines. (C) WNV-specific IFN-γ secretion by CD4 T cells in control (H1, 
H3, H5, H8, H10 and H12, with unfilled and uncolored symbols), vaccinated horses (H4, H6, 
H7, H9 and H11, with filled and colored symbols). The line/scatter plot instead of box and 
whisker plot showed the dynamic trends in host immune response to vaccination during a series 
of time points, but with high variation among animals. The stars indicated a statistically 
significant difference between control and vaccination animals. The inverted red-filled triangles 
on the X axis indicated the days for vaccination. 
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Fig. 1.2. Vaccination with an inactivated WNV vaccine elicited WNV-specific Th2 CMI in  
yearling horses. Samples were from exactly the same treatments, stained the same way as in 
Fig. 1.1, except stained for IL-4 instead of IFN-γ. Figure legends were the same as in Fig. 1.1. 
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Fig. 1.3. Vaccination with an inactivated WNV vaccine elicited WNV-specific CTLs in 
yearling horses. Samples were from exactly the same treatments, stained the same way as in 
Fig. 1.1, except stained for CD8 instead of CD4.  Figure legends were the same as in Fig. 1.1. 
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Fig. 1.4. Comparison of WNV-specific Th1 and Th2 CMI (flow cytometric data) in  
vaccinated healthy yearling and adult horses. (A) Yearling horses (n=5) have both Th1 and 
Th2 cell-mediated immune responses (with a Th1 bias) to WNV vaccination. The data were from 
Fig. 1.1 and 2. (B) Adult horses (n=6) have much stronger Th1-biased cell-mediated immune 
response to WNV. These horses were previous vaccinated against WNV. These data were 
obtained 1 and 2 weeks after the last booster immunization. Their PBMCs, except being cultured 
for 3 days instead of 4 days, were treated and stained exactly the same way as shown in Fig. 1.1 
and 1.2. The difference between IFN-γ and IL-4 is significant, p<0.002. Since most of the data 
were not normally distributed, box-and-whisker plots in Sigmaplot 10 (Systat Software, Inc., San 
Jose, CA) were applied to show the data (same for Fig. 1.5). The solid thick blue or dashed thick 
black bar is for the mean, the thin black bar for the median. 
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Fig. 1.5. Comparison of relative fold changes in expression of WNV-specific IFN-γ and IL-4  
by PBMCs from vaccinated healthy yearling and adult horses. Quantitative one-step RT-
PCR was performed to quantify the relative expression of IFN-γ and IL-4 with 18S rRNA as the 
internal control. (A) The expression of Th1 cytokine IFN- γ and Th2 cytokine IL-4 in PBMCs 
from vaccinated yearling (n=5) and adult horses (n=6) after WNV antigen stimulation in vitro. 
The solid thick blue bar is for the mean, the thin black bar for the median. The samples collected 
at 2 weeks after the 1st booster vaccination for yearling horses, and at 2 weeks after the booster 
vaccination for adults were compared. (B) Change in ratio of IFN- γ to IL-4 expression by 
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PBMCs in yearling and adult horses after WNV antigen stimulation in vitro. The difference 
between yearling and adult horses is statistically significant (p value = 0.02). 
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Fig. 1.6. Vaccination with an inactivated WNV vaccine elicited strong WNV-specific CD4 T  
cell proliferation in yearling horses. Flow cytometric assay of WNV-specific CD4 T cell 
proliferation from a typical vaccinated horse was shown in panels A and B, all cells were CFSE-
stained and cultured for 5-6 days. (A) CFSE-stained PBMCs were not stimulated purified WNV 
antigens. (B) CFSE-stained PBMCs were stimulated with purified WNV antigens (20 ug preM+ 
E proteins/ml). Cells were only surface-stained. For panels C, D and E, the figure legends were 
the same as in Fig. 1.1. (C) The frequency or percentage of WNV-specific CD4 T cells 
proliferation for control and vaccinated horses. (D) The percentage of WNV-specific 
proliferating CTLs for control and vaccinated horses. (E) The percentage of WNV-specific MHC 
class II+ cell proliferation for control and vaccinated horses. 
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Abstract 
 
            Innate immunity relies on a series of germline-encoded pattern recognition receptors 
(PRRs), such as Toll-like receptors (TLRs), to detect conserved microbial components. TLR9 is 
typically expressed intracellularly in immune cells such as dendritic cells and recognizes 
unmethylated bacterial or viral cytosine-phosphate-guanine DNA (CpG-DNA). To investigate 
innate immune responses through TLR9 signaling pathway in horses, we cloned and 
characterized equine TLR9. Protein sequence analysis shows that equine TLR9 has a typically 
conserved cytosolic Toll/Interleukin-1 receptor (TIR) domain, three leucine-rich repeat (LRR) 
motifs, and more than 82% identity to human, monkey, bovine, canine, feline, porcine and ovine 
orthologs. Equine TLR9 mRNA was expressed in the spleen, lymph nodes, and peripheral blood 
leukocytes. Flow cytometric analysis of equine TLR9 expression using a cross-reactive TLR9 
mAb identified high constitutive expression of equine TLR9 in PMNs, CD4+ and CD8+ T 
lymphocytes as well as other leukocytes; similar to human TLR9 expression. The conservation 
of equine TLR9 and a high expression profile in leukocytes suggests that equine TLR9 is a 
frequent target for unmethylated CpG-DNA, an essential mechanism for the activation of innate 
immunity. 
 
Keywords: equine TLR9, PMBC, PMN 
 
 
1. Introduction 
Innate immunity relies on a series of germline-encoded pattern recognition receptors 
(PRRs), such as Toll-like receptors (TLRs), to detect pathogen-associated molecular patterns 
(PAMPs) (Akira & Takeda, 2004;Akira, Uematsu et al., 2006;Janeway, Jr. & Medzhitov, 2002). 
TLRs have recently emerged as key PRRs that detect microbial infections and trigger 
antimicrobial host defense responses. Thus they play a crucial role in the activation of innate 
immunity and enhance adaptive immunity (Akira & Takeda, 2004;Pasare & Medzhitov, 
2004;Takeda, Kaisho et al., 2003;Werling & Jungi, 2003).  
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Twelve TLRs have been identified in mammals. TLR9 was first cloned from humans and 
mice (Chuang & Ulevitch, 2000;Hemmi, Takeuchi et al., 2000) and subsequently from domestic 
animals including swine (Shimosato, Kitazawa et al., 2003), canine (Hashimoto, Asahina et al., 
2005), feline (Ignacio, Nordone et al., 2005), bovine and ovine (Griebel, Brownlie et al., 2005). 
TLR9 belongs to the interleukin-1 receptor/Toll-like receptor superfamily with a conserved 
cytosolic TIR domain and a few leucine-rich repeat (LRR) motifs (Akira, Uematsu et al., 
2006;Bowie & O'Neill, 2000).  
TLR9 is mainly expressed in PBMCs and lymphoid tissues such as lymph nodes and the 
spleen (Chuang & Ulevitch, 2000;Hashimoto, Asahina et al., 2005). In humans, plasmacytoid 
dendritic cells have the highest level of TLR9 expression (Hornung, Rothenfusser et al., 2002). 
The TLR9 specific ligand is unmethylated cytosine-phosphate-guanine DNA (CpG-DNA). 
Evidence to support the CpG-TLR9 interaction includes the finding that TLR9 deficient mice 
failed to respond to CpG-DNA (Hemmi, Takeuchi et al., 2000). Unmethylated CpG-DNA binds 
to TLR9, resulting in activation of antigen presenting cells, which subsequently activate T-
lymphocytes to secret proinflammatory cytokines such as IFN-γ that promote T-helper type 1 
(Th1) immunity. Th1 immunity is essential to control intracellular viral and bacterial infections, 
and the CpG-TLR9 interaction has been explored as a potential therapy for neoplastic and 
allergic diseases (Krieg, 2006;Krieg, 2007). Investigations involving TLR9-based 
immunotherapy for allergic diseases such as asthma have shown that CpG-DNA treatment can 
inhibit allergic or Th2-driven inflammation (Hayashi & Raz, 2006). 
Rhodococcus equi is a facultative intracellular bacterium that can cause fatal 
bronchopneumonia in foals 2-5 months of age. Clearance of R. equi requires IFN-γ from CTL 
and CD4+ T cells (Hines, Stone et al., 2003;Kohler, Stone et al., 2003;Patton, McGuire et al., 
2004;Patton, McGuire et al., 2005). TLR9-based immunotherapy, specifically targeting Th1-
induced immunity may provide a therapeutic mechanism to aid in control of R. equi infection in 
young horses. Equine recurrent airway obstruction (RAO) is one of the most common equine 
respiratory diseases, affecting up to 50% of horses with respiratory diseases worldwide (Bowles, 
Beadle et al., 2002). RAO is characterized by increased expression of Th2 cytokines such as 
interleukin (IL)-4 and IL-5, and decreased expression of Th1 cytokines such as IFN-γ in 
bronchoalveolar immune cells (Bowles, Beadle et al., 2002;Cordeau, Joubert et al., 
2004;Dewachi, Joubert et al., 2006;Giguere, Viel et al., 2002;Lavoie, Maghni et al., 2001), 
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suggesting a shift in the Th1/Th2 balance of affected individuals. TLR9-based immunotherapy 
may provide a mechanism to restore the Th1/Th2 balance and influence the host allergic 
response.  Prior to application of TLR9-based immunotherapy in horses for either intracellular 
infections or RAO, it is of fundamental importance to clone and fully characterize equine TLR9. 
Previous investigations have not included horses as a host for investigation of TLR9 expression 
with few studies demonstrating potential immunomodulatory effects of CpG-DNA used in the 
equine host (Flaminio, Borges et al., 2007;Lopez, Hecker et al., 2006;Wattrang, Berg et al., 
2005). Here we report the molecular cloning, characterization, and expression of equine TLR9. 
 
2. Materials and Methods 
 
2.1 Primer design for TLR9 cloning 
 
Primers used to clone equine TLR9 were designed based on the homology of TLR9 
sequences of human (accession NM_017442), monkey (accession AY788894), bovine 
(accession AY859726), canine (accession AY859723), feline (accession AY859724), ovine 
(accession AY859727), swine (accession AY859728), and murine (accession AB045181) hosts. 
 
2.2. Tissue sampling and RNA isolation 
All animal protocols were approved by the Kansas State University Institutional Animal 
Care and Use Committee. Horse tissues were collected from three adult, euthanized quarter 
horses. After euthanasia, equine tissue samples for RNA isolation were collected immediately, 
snap frozen in liquid nitrogen and stored at -80 oC for further total RNA isolation. Samples 
collected included PBMCs, lymph nodes, spleen, kidney, liver, lung, small intestine, stomach, 
colon, and heart. Total RNA was isolated from tissues other than PBMCs using TRIzol® reagent 
(Sigma-Aldrich, St. Louis, MO) or PBMCs using an RNeasy Mini Kit (Qiagen, Valencia, CA), 
following the protocols with the reagent or kit. Extracted total RNA was also treated with DNase 
I (Invitrogen, Carlsbad, CA) for 20 to 30 min and purified in RNeasy Mini Kit. 
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2.3. Rapid amplification of cDNA 5’ & 3’ ends (RACE) 
 
DNase I-treated total RNA from lymph nodes or PBMCs was used to synthesize cDNA. 
3’ RACE was performed with FirstChoice® RLM-RACE (Ambion, Austin, TX) and 5’ RACE 
utilized SMART™ RACE cDNA Amplification Kit (Clontech, Mountain View, CA). PCR 
amplified equine TLR9 fragments were sequenced directly (DNA Sequencing and Genotyping 
Facility, Kansas State University). Overlapping sequences were analyzed correctly and aligned. 
 
2.4. Cloning and transfection of equine TLR9 
The full-length coding sequence of equine TLR9 (GenBank accession no. DQ390541) 
was amplified by PCR from cDNA with Phusion™ High-Fidelity DNA Polymerase (New 
England Biolabs, Ipswich, MA) and the following primer pair: 
CACCATGGGCCCTTGCCATGGTGC (sense) and CTACTCAGCCATCGTCGGGCCCCG 
(antisense). We then cloned it into a pcDNA™3.1D/V5-His-TOPO® vector (Invitrogen) 
following the protocol with the pcDNA™3.1 Directional TOPO® Expression Kit. This 
expression vector has a human cytomegalovirus (CMV) immediate early enhancer/promoter for 
high-level constitutive expression of the targeted gene and a neomycin resistance gene. 
Authenticity of equine TRL9 cloning was confirmed by plasmid sequencing. The 
pcDNA™3.1D/V5-His-TOPO® with equine TLR9 insert was transfected into human embryonic 
kidney (HEK) 293A cells (Invitrogen) using DOTAP (Roche Applied Science) as the 
transfection reagent. We chose HEK293 cell line because it has been widely utilized to study the 
mammalian TLR9 signaling pathway (Bauer, Kirschning et al., 2001;Heil, Hemmi et al., 
2004;Heil, hmad-Nejad et al., 2003). The pcDNA™3.1D/V5-His/lacZ, a 8586 bp control vector 
with the irrelevant gene for β−galactosidase, was utilized as the transfection control.  For 
transfection, 1.5 μg plasmid DNA mixed with 1.5 μl DOTAP was used for 1 x 106 293A cells 
(approximately passage 15) in serum-free media. One hour after transfection (approximately 
70% confluence), serum-free media was replaced by complete media (Dulbecco’s modified eagle 
medium with 10% FBS, 0.1 mM non-essential amino acids, 2 mM L-glutamine, and 1% 
penicillin-streptomycin, Invitrogen), but without geneticin (Invitrogen). After culture for 24 h at 
37 oC in a humidified sterile incubator with 5% CO2, geneticin was added (a final concentration 
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of 400 ug/ml) to induce equine TLR9 expression in 293A cells. Cells were cultured for another 
24h before harvesting for total RNA isolation and examination of transient equine TLR9 
expression by flow cytometry. We confirmed exclusive equine TLR9 expression in equine 
TLR9-transfected 293A cells by reverse transcriptase (RT)-PCR using a OneStep RT-PCR kit 
(Qiagen) and equine TLR9-specific primers (Table 2.1) with 30 cycles of PCR reaction. The RT-
PCR or PCR (no RT as control) was performed with 25 ng total RNA in 25 μl reaction plus 0.6 
μM final primer concentration for each forward and reverse primer. RT-PCR of 18S and 28S 
rRNA was performed to serve as internal controls.  The cross-species reactivity of a mouse anti-
human TLR9 mAb (Imgenex, San diego, CA) with equine TLR9 in equine TLR9-transfected 
293A cells was tested by flow cytometry. The endogenous human TLR9 expression in HEK293 
cells, with or without transfection, was also detected by flow cytometry as well as RT-PCR using 
human TLR9-specific primer pair (Table 2.1) with 35 cycles of PCR reaction. 
 
2.5. Quantitative RT-PCR 
 
Primers (Table 2.1) for quantitative RT-PCR were designed using Beacon Designer 4.0 
(PREMIER Biosoft International, Palo Alto, CA) for SYBR Green I assay of DNA synthesis. 
Quantitative PCR was performed on DNase I-treated total RNA samples from individual animals 
using a OneStep RT-PCR kit (Qiagen) in the presence of 0.2X SYBR Green I (Invitrogen). 
Quantitative PCR for 18S rRNA (as an internal control) and TLR9 was performed in 25-ul 
reactions with 50 ng of total RNA and 0.6 μM final primer concentration for each forward and 
reverse primer, using a Bio-Rad iCycler iQ Real Time PCR System. The real-time PCR 
specificity was also confirmed by melting curve analysis. The PCR amplification efficiency of 
TLR9 and 18S rRNA for each reaction was estimated by linear regression (Ramakers, Ruijter et 
al., 2003), approximately 80% to 100% for TLR9 and 100% for 18S rRNA. The relative gene 
expression ratio of TLR9 to 18S rRNA was calculated using the formula derived by Schefe et al. 
(Schefe, Lehmann et al., 2006) and threshold cycle numbers (CT) that were automatically 
determined by the Optical System Software (Version 3.1) with the Bio-Rad iCycler iQ Real 
Time PCR System. 
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2.6. PMNs and PBMCs isolation 
Following skin preparation with 70% ethanol, blood was collected from the jugular vein 
of healthy young or adult quarter horses into syringes with heparin (50 U/ml). Equine PMNs and 
PBMCs were isolated by density-gradient separation using Histopaque®-1077 (Sigma-Aldrich). 
Briefly, blood samples were incubated at room temperature for 30 min to sediment RBCs. The 
upper phase was transferred gently on the top of Histopaque 1077 in a new tube and centrifuged 
at 400 g for 30 min. PBMCs, in the cloudy layer, were harvested and transferred to a new tube 
and washed twice with PBS. The pellet (PMNs) was transferred to a new tube, resuspended in 
RBC lysis buffer (8.26 g NH4Cl, 1 g KHCO3 and 0.037 g EDTA in 1 l distilled H2O, filter-
sterilized) for 3 min, and then washed twice with PBS. PMNs were stained with HEMA 3 (Fisher 
Scientific, Kalamazoo, MI) and examined morphologically. Approximately granulocytes with a 
yield of 99% were routinely obtained, of which 96% were neutrophils. 
 
2.7. Stimulation of PBMC by PHA 
Equine PBMCs were cultured at 1x 106/ml in complete media (RPMI 1640 (Hyclone, 
Logan, UT) with 10% autologous plasma and 1% penicillin-streptomycin) with or without 5 
ug/ml PHA (Roche Applied Science, Indianapolis, IN). After culturing for 3 or 4 days at 37 oC in 
a humidified sterile incubator with 5% CO2, cells were harvested for flow cytometric analysis of 
TLR9 expression. Cells used for intracellular IFN-γ labeling were treated with GolgiplugTM 
(protein transport inhibitor Brefeldin A, BD Sciences, San Jose, CA) for 12 hr before harvesting 
for flow cytometric analysis. 
 
2.8. Flow cytometry 
 
After the mouse anti-human TLR9 mAb (Clone 26C593.2, FITC or PE conjugated, 
Imgenex) was confirmed to be cross-reactive to equine TLR9 by RT-PCR and flow cytometry, 
equine TLR9 expression in leukocytes was investigated by flow cytometry, staining with 1 μg 
mAb/106 cells.  
Primary mouse anti-equine CD4 (HB61A), anti-equine CD8 (HT14A), anti-swine 
CD172a (DH59B, for monocyte/granulocyte specific antigen(Tumas, Brassfield et al., 1994) 
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mAbs were purchased from VMRD (Pullman, WA). Secondary goat anti-mouse Abs, APC-
conjugated, were from Invitrogen. PBMCs and PMNs were fixed and permeablized for TLR9 
mAb staining after surface labeling for CD4, CD8, and CD172a, following the protocol with the 
FIX & PERM kit (Invitrogen).  The mAbs (Clone MOPC-21, FITC or PE conjugated) used as 
isotype controls were purchased from BD Sciences.  
Intracellular IFN-γ was labeled with mouse anti-bovine IFN-γ-FITC (CC302, AbD 
Serotec, Raleigh, NC) due to its confirmed cross-species reactivity with equine IFN-γ (Paillot, 
Daly et al., 2005), following the protocol with the FIX & PERM kit (Invitrogen). 
Single-color histograms were generated with CellQuest software (BD Sciences), Two-
color dot plot analysis was performed with Winlist 6.0 (Verity Software House, Topsham, ME). 
 
2.8. Statistics 
The Kolmogorov-Smirnov (K-S) two sample test (in CellQuest) was used for overlaid 
histogram comparison. The p-value less than 0.05 is considered significant. 
 
 
3. Results 
 
3.1. Cloning of equine TLR9  
 
We designed primers based on the homology of mammalian TLR9 DNA sequences and 
amplified overlapped equine TLR9 fragments from cDNA by PCR. Sequence analysis of these 
fragments revealed a 3371-bp equine TLR9 gene (GenBank accession no. DQ390541), which 
included the 5’ and 3’ un-translated regions as well as the coding sequence of 3096 bp encoding 
1031 amino acids. The deduced equine TLR9 protein has more than 82% identity to human, 
monkey, bovine, canine, feline, swine and ovine orthologs, but less than 75% identity to murine 
orthologs (Fig. 2.1). It can be inferred that murine TLR9 genes are evolutionarily more distant 
from the primate TLR9 orthologs when compared with those of domestic mammals. Protein 
sequence analysis in Conserved Domain Database (Marchler-Bauer, Anderson et al., 2007) 
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showed equine TLR9 has a typically conserved cytosolic TIR domain and three leucine-rich 
repeat (LRR) motifs. We blasted the equine TLR9 mRNA sequence in the recently release 
equine genomic sequence 
(http://www.ncbi.nlm.nih.gov/genome/seq/BlastGen/BlastGen.cgi?taxid=9796) that was based 
on the DNA source of a female thoroughbred horse named "Twilight" from Cornell University in 
Ithaca, New York. It was determined equine TLR9 is located on the Equus caballus (horse) 
chromosome 16 with one intron between AT and G of the start codon. We surmised that this 
intron localization is consensus among mammals even though their TLR9 genes are located in 
different chromosome after we did similar genome blast. A single nucleotide polymorphism 
(SNP: GAT versus GAC) between quarter horse and thoroughbred breeds was found at base 240 
of equine TLR9 coding sequence, even though the TLR9 sequence has not been annotated yet in 
the released equine genomic sequence. 
 
3.2. Cross-species reactivity of anti-human TLR9 mAb with equine TLR9 
 
The antigenic peptide (268-284 amino acids) of human TLR9 is 82% homologous to 
equine TLR9. From this finding we reasoned that anti-human TLR9 mAb would likely cross-
react with equine TLR9 and the exchange of three out of 17 amino acids in the antigenic peptide 
would minimally affect its affinity for the anti-human TLR9 mAb. To confirm the cross-species 
reactivity of anti-human TLR9 mAb, we expressed equine TLR9 protein in HEK293 cells, which 
have a low level of human TLR9 transcription (Hornung, Rothenfusser et al., 2002;Khvalevsky, 
Rivkin et al., 2007). We cloned the full-length equine TLR9 coding sequence as described 
previously and transiently expressed it in 293A cells. Our RT-PCR results (Fig. 2A.) with equine 
TLR9-specific primers confirmed the exclusive expression of equine TLR9 in 293A cells when 
transiently transfected with pcDNA™3.1D/V5-His-TOPO® vector plus equine TLR9 insert. We 
further confirmed this exclusive equine TLR9 expression, a small, but consistent and significant 
increase of TLR9 expression in 293A cells when transfected with equine TLR9 compared to 
vector (K-S statistic p-value is less than 0.001 for either the marker areas or the whole 
histograms), was detected by flow cytometry (Fig. 2.2B). Especially the marked population with 
TLR9 staining accounted for 53.3% of the equine TLR9-transfected 293A cells, 22.3% higher 
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than that of the vector-transfected 293A cells. Although the human TLR9 mRNA level was very 
low (Fig. 2.2C) based on RT-PCR, its protein level in 293A cell was found to be surprisingly 
high (Fig. 2.2B), which agrees with the reported flow cytometric data using a different anti-
human TLR9 Ab (Hoene, Peiser et al., 2006). RT-PCR (Fig. 2.2C) as well as quantitative real 
time RT-PCR (data not shown) showed no difference in human TLR9 mRNA level among 293A 
cells, vector-transfected 293A cells and equine TLR9-transfected 293A cells. No difference in 
human TLR9 expression between 293A cells and vector- transfected 293A cells was found by 
flow cytometric analysis (data not shown). These data support that anti-human TLR9 mAb cross-
reacts with equine TLR9. 
 
3.3. Expression of equine TLR9 in different tissues and immune cell subsets 
 
Quantitative PCR was used to examine TLR9 expression in various tissues. Expression 
levels were compared among other tissues to that of lymph nodes (arbitrarily set as 100%), 18S 
ribosomal RNA was used as an internal control. Equine TLR9 is primarily, constitutively 
expressed in PBMCs, lymph nodes, and the spleen (Fig. 2.3), consistent with the fact that these 
tissues are enriched with leukocytes.  The level of TLR9 in PBMCs is about two to three folds 
higher than that in lymph nodes and the spleen in which their leukocytes do not account for 
100% of its cells in the tissues. 
After confirming the cross-species reactivity of human TLR9 mAb with equine TLR9, 
we examined the specific level of TLR9 expression in specific leukocyte subsets. TLR9 has been 
shown to be mainly expressed in intracellular compartments (Latz, Schoenemeyer et al., 
2004;Leifer, Brooks et al., 2006;Leifer, Kennedy et al., 2004). We reasoned that this also would 
be the case for equine TLR9. Surface and intracellular labeling of equine TLR9 showed that it 
was minimally expressed on the plasma membrane and almost exclusively expressed 
intracellularly in all leukocytes (Fig. 2.4).  
We used PHA to enhance TLR9 expression in PBMC. PHA significantly enhanced 
equine TLR9 expression by PBMC (Fig. 2.5A) because the mitogenic activity of PHA 
consistently induced pronounced IFN-γ synthesis (Fig. 2.5B) and IFN-γ could subsequently 
enhance TLR9 expression (Uchijima, Nagata et al., 2005). 
 36
We further investigated TLR9 expression in equine leukocyte subsets including PMNs, 
CD4 and CD8 T cells using two-color flow cytometric analysis. Approximately 90% of the 
PMNs, CD4 and CD8 T cells exhibited TLR9 expression (Fig. 2.6). This high constitutive 
expression of TLR9 in leukocytes may suggest an important role for TLR9 in equine innate 
immunity. 
 
4. Discussion 
 
Since the discovery of the Toll gene for the establishment of dorso-ventral polarity in the 
developing embryo in Drosophila (Hashimoto, Hudson et al., 1988) and its antifungal function in 
adult flies (Lemaitre, Nicolas et al., 1996), many TLRs, all with highly conserved TIR domains, 
have been cloned in mammals and shown  to play a critical role in linking innate and adaptive 
immunity (Akira & Takeda, 2004;Janeway, Jr. & Medzhitov, 2002;Pasare & Medzhitov, 
2004;Takeda, Kaisho et al., 2003). We report that equine TLR9 is highly homologous to other 
mammalian orthologs and has a conserved TIR domain and three LRR motifs. Similar to canine 
and human TLR9 (Chuang & Ulevitch, 2000;Hashimoto, Asahina et al., 2005), equine TLR9 is 
mainly expressed in peripheral leukocytes and leukocyte enriched tissues such as lymph nodes 
and the spleen (Fig. 2.3), low level expression exists in other tissues such as heart and lung, 
which likely reflects minimal leukocyte infiltration. 
We confirmed the cross-species reactivity of a mouse anti-human TLR9 mAb to equine 
TLR9 due to high homology between human and equine TLR9, using both RT-PCR and flow 
cytometry (Fig. 2.2). In addition, flow cytometry and RT-PCR analyses of HEK293 cells 
revealed low, constitutive endogenous human TLR9 expression. These data were consistent with 
previous reports (Hoene, Peiser et al., 2006;Hornung, Rothenfusser et al., 2002;Khvalevsky, 
Rivkin et al., 2007). The equine TLR9 expression in 293A cells (Fig. 2.2B) after equine TLR9 
transfection was consistent.    
Although increased TLR9 expression in 293A cells was observed after equine TLR9 
transfection, its level was not drastic.  Reasons for low equine TLR9 expression in 293A cells 
following transfection may be explained by a few possibilities.   Low, but preexisting 
endogenous human TLR9 expression in 293A cells accounted for some of the baseline receptor 
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expression.  In addition, the exchange of three out of 17 amino acid residues in the antigenic 
peptide in equine TLR9 compared to that in human TLR9 may affect affinity to the anti-human 
TLR9 mAb, resulting in an impaired determination of total TLR9 expression.  It is also possible 
that transfection was not optimal, resulting in a blunted level of equine TLR9 expression.  
Finally, it should be considered that equine TLR9 expression may have been regulated in 293A 
cells because TLR9 can bind to CpG motifs in plasmid DNA (Cornelie, Hoebeke et al., 2004).  
In this instance, plasmid existence is essential for conferring antibiotic resistance in media 
containing geneticin.   If CpG-TLR9 interaction resulted in endocytic plasmid removal, then 
correspondingly the cell survial in geneticin-containing media could be compromised.  This may 
explain why we could not obtain stable equine TLR9 transfection in 293A cells. However, we 
were still able to obtain consistent and significant transient equine TLR9 expression in 293A 
cells as well as in ATCC HEK293 cells (data not shown) to determine the cross-reactivity of an 
anti-human TLR9 mAb even though HEK293 cells constitutively express low level of human 
TLR9. 
The cross-species reactivity of anti-human TLR9 mAb was exploited to investigate 
equine TLR9 expression in immune cell subsets using flow cytometry (Fig. 2.4-6). We 
confirmed that TLR9 expression is almost exclusively expressed and localized intracellularly 
(Fig. 2.4), presumably limited to the endoplasmic reticulum, endosomes and lysosomes (Latz, 
Schoenemeyer et al., 2004;Leifer, Brooks et al., 2006;Leifer, Kennedy et al., 2004). Additional 
studies are needed to confirm equine TLR9 expression in these organelles. Intracellular TLR9 
localization reflects the critical need for host clearance of intracellular pathogens (Barton, Kagan 
et al., 2006) as well as host protection against autoimmune diseases such as systemic lupus 
erythematosus (Anders, 2005;Rahman & Eisenberg, 2006). 
High TLR9 expression was detected within equine PMNs, CD4 and CD8 T cells as well 
as in other leukocytes (Fig. 2.4 and 2.6). High levels of TLR9 transcription (Hornung, 
Rothenfusser et al., 2002) have been shown in human plasmacytoid dendritic cells and B cells as 
well as some level in NK and T cells. Recent data (Fransson, Benson et al., 2007) have 
demonstrated that human TLR9 protein is expressed in neutrophils, eosinophils, and basophils as 
well as in monocytes and lymphocytes. Our data are consistent with these findings, although 
equine immunologic investigations are somewhat limited due to a paucity of equine-specific 
immunologic reagents. 
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Constitutive TLR9 expression in both human (Fransson, Benson et al., 2007;Hornung, 
Rothenfusser et al., 2002) and equine leukocytes presents a similar profile, suggesting the 
potential similarity in function of TLR9 between humans and horses. Previous investigations 
have shown that TLR9, especially in professional APCs (B cells, dendritic cells, and 
macrophages), is involved with host immune response to Herpes simplex virus (Lund, Sato et al., 
2003), human papillomavirus (Hasan, Bates et al., 2007), murine cytomegalovirus (Krug, French 
et al., 2004;Tabeta, Georgel et al., 2004), Mycobateria tuberculosis (Bafica, Scanga et al., 2005), 
Propionibacterium acnes (Kalis, Gumenscheimer et al., 2005), and Trypanosoma cruzi infection 
(Bafica, Santiago et al., 2006) through mediating production of proinflammatory cytokines such 
IL-12 and IFN-γ, and further modulating the host adaptive immune response. Whether equine 
TLR9 has similar biological function when compared with the human homologue requires 
further investigation.  
Granulocytes, which are primarily composed of neutrophils, constitute a critical 
component of host innate immunity. Most TLRs, including TLR9, have been found expressed in 
PMNs (Fransson, Benson et al., 2007;Hayashi, Means et al., 2003;Parker, Whyte et al., 
2005;Trevani, Chorny et al., 2003), however, the role of TLR9 expression in this leukocyte 
subset (as well as T cells) requires further elucidation in most mammalian species including 
horses. Once TLR9 is fully functionally characterized, the TLR9 agonist may be implemented as 
a vaccine adjuvant to enhance host Th1 immunity against intracellular pathogens such as 
Rhodococcus equi, or an immunostimulant to attenuate the symptoms of the Th2-biased equine 
respiratory diseases such as RAO. 
In conclusion, our data indicate that equine TLR9 is highly homologous to orthologs in 
other mammals. It is mainly expressed in the spleen, lymph nodes, and intracellularly in 
peripheral blood leukocytes. Although equine TLR9 expression is constitutive, it can be 
enhanced by PHA, likely a result of enhanced IFN-γ secretion by T lymphocytes. The 
conservation of equine TLR9 and high expression profile in leukocytes may suggest that equine 
TLR9 is a frequent target by unmethylated CpG-DNA for activation of innate immunity and 
potentially for enhancement of antigen-specific Th1 immunity against intracellular pathogens. 
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 Table 2.1. Primers for conventional and quantitative real time RT-PCR 
Gene Primer Sequence (5’ → 3’) Amplicon 
Length (bp) 
GenBank 
accession No. 
Equine TLR9 Forward GTGACTGGCTACCTGGCAAGAC 337 DQ390541 
  Reverse TGGTTATAGAAGTGGCGGTTGTCC     
Human TLR9 Forward CCACAACAACATCCACAGCCAAGT 266 NM_017442 
 Reverse TCCACCACTTAAAGAAGGCCAGGT   
18S rRNA Forward ATGCGGCGGCGTTATTCC 204 AJ311673 
NR_003286 
  Reverse GCTATCAATCTGTCAATCCTGTCC     
28S rRNA Forward CGGGTAAACGGCGGGAGTAAC 109 NR_003287 
  Reverse TAGGTAGGGACAGTGGGAATCTCG     
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FIGURES 
 
 
Fig. 2.1. The phylogenetic tree of mammalian TLR9. The unrooted tree was generated using 
ClustalX program by neighbor-joining method and visualized by Treeview (Page, 1996). Scale 
bar represents 0.1 amino acid substitution per site. 
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Fig. 2.2. Equine TLR9 was transfected and transiently expressed in 293A cells.  
“293A+vector” means 293A cells transfected with control vector (The pcDNA™3.1D/V5-
His/lacZ), “293A+equine TLR9” means 293A cells transfected with the equine TLR9 insert in 
the plasmid. In panel A (2% agarose gel picture), 1 is for RNA samples from “293A+vector”, 2 
is for RNA samples from “293A+equine TLR9”.  Equine TLR9 expression in 293A cells was 
confirmed by one-step RT-PCR using a final 0.6 μM gene-specific primers (Table 2.1), 25 ng 
DNase I-treated total RNA, and 30 PCR cycles in a 25-ul reaction. Total RNA was also 
confirmed with no DNA contamination by PCR alone (CK: no reverse-transcription control). 
18S and 28S ribosomal RNA levels were examined as internal controls. The left lane in panel A 
is a 100bp ladder (Promega) with 500 bp as the brightest one. In panel B, equine TLR9 was 
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transfected and transiently expressed in 293A cells and human TLR9 antibody (Imgenex) was 
confirmed cross-reactive to equine TLR9 by flow cytometry. The marked areas or channels 
showed the difference in TLR9 staining in 293A cells transfected with the vector or plus equine 
TLR9. The K-S statistics was used to compare these two overlaid histograms. The p-value is less 
than 0.001. Similar results were repeated 6 times. In panel C, human TLR9 expression was 
confirmed by one-step RT-PCR with gene-specific primers and 35 PCR cycles, in which “No RT 
CK” is for controls with PCR but without reverse-transcription, 3 & 4 are two transfection 
repeats with plasmids containing the same equine TLR9 insert but from 2 different bacterial 
colonies. Data for 18S rRNA as equal loading of total RNA are not shown here. 
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Fig. 2.3. Equine TLR9 is mainly expressed in PBMCs, lymph nodes, and the spleen. 
TLR9 transcription level in tissues was examined by quantitative one-step RT-PCR with 18S 
ribosomal RNA as an internal control. TLR9 transcription level was normalized by that in lymph 
nodes. The relative TLR9 mRNA abundance from three horses was averaged. Error bar shows 
the standard deviation. 
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TLR9-  
Fig. 2.4. TLR9 is almost exclusively expressed intracellularly.  
Heparinized horse blood was incubated at room temperature for 30 min to sediment RBCs. 
Leukocytes from the plasma were then subject to “TLR9 surface staining” with cross-reactive 
anti-human TLR9 mAb (PE-conjugated) or fixed and permeablized for “TLR9 intracellular 
staining” with anti-human TLR9 mAb. The isotype control for TLR9 staining was also PE-
conjugated. Similar results were obtained from 6 horses. 
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Fig. 2.5. PHA enhanced the expression of equine TLR9 (panel A) and IFN-γ (panel B)  
determined by flow cytometry. PBMCs were cultured in complete media with and without 
PHA (5 ug/ ml with 1x 106 PBMC /ml complete media) for 4 days before harvest for 
intracellular TLR9 staining with the PE-conjugated anti-human TLR9 mAb. PBMCs used for 
IFN-γ staining were treated with Golgiplug for 12 hr and harvested for flow cytometric analysis. 
Viable cell population was identified by propidium iodide (PI) staining of different PBMCs 
treated alike because horse viable PBMCs after culture differ from dead ones not only in no PI 
staining, but also in cell size and granularity. This feature of cultured horse PBMCs remains 
relatively constant so that  the dead cells can be easily gated out. (data not shown). The isotype 
control for TLR9 staining was PE-conjugated. The isotype control for IFN-γ staining was FITC-
conjugated. Similar results were obtained from 6 horses. 
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Fig. 2.6. TLR9 is expressed in most equine leukocytes. Leukocytes were surface-stained for 
PMNs (panel B), CD4 (panel D) and CD8 T cells (panel E), then were fixed and permeablized 
for TLR9 staining. The anti-human TLR9 mAb was either FITC- or PE-conjugated. Panel A: 
isotype control for PMNs’ TLR9 staining was PE-conjugated; Panel C: isotype control for PBLs’ 
TLR9 staining was FITC-conjugated. In both panel A and C, the APC-congujated secondary Abs 
were utilized as isotype controls for PMN, CD4, and CD8 surface staining. Percentage of cells in 
each quadrant is shown for each staining. Similar results were obtained from 8 horses. 
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 CHAPTER 3 - CpG-DNA enhances equine innate immunity 
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Abstract 
 
Unmethylated CpG-DNA, the ligand of Toll-like receptor 9, has been extensively tested 
in mice, humans and many domestic animals for immunological impact and potential as a 
vaccine adjuvant. Research on CpG-DNA in equine innate immunity remains limited. The 
impact of CpG-DNA on equine neutrophils has not been reported. To study innate immune 
responses to CpG-DNA in horses, PMNs, PBMCs and monocyte-derived dendritic cells 
(moDCs) were stimulated with CpG-DNA and cytokine mRNA expression profiles were 
investigated using quantitative reverse transcriptase (RT)-PCR. CpG-DNA significantly 
stimulated IL-8 and TNF-α expression in PMNs, induced expression of IFN-α, IFN-β, IFN-γ, 
IL-6, IL-8 and IL-12p35 in PBMCs as well as IFN-α and IFN-γ in moDCs. The enhanced 
expression of IFNs in immune cells by CpG-DNA not only is crucial for host viral clearance, but 
also may play an important role in mediating host immune responses due to IFNs’ anti-
inflammatory activity. Tested CpG-DNA showed potential as vaccine adjuvants to enhance 
CTLs and T helper 1 (Th1) cell-mediated immunity (CMI) against intracellular pathogens 
because of their apparent induction of type I IFNs and Th1-specific cytokines such as IL-12p35 
and IFN-γ. These data provide a basis for further investigation of CpG- DNA as a potentially 
effective vaccine adjuvant in horses. 
 
Key words: Equine, innate immunity, CpG-DNA, IFN 
 
1. Introduction 
Toll-like receptor 9 (TLR9), a highly conserved endosomal pattern recognition receptor 
(PRR) in mammalian innate immunity, senses unmethylated bacterial or viral cytosine-
phosphate-guanine DNA (CpG-DNA) (Kawai and Akira, 2006; Eisenacher et al., 2008; Zhang et 
al., 2008). Activation of innate immunity through TLR9 signaling can promote the production of 
interferons (IFN-α, IFN-β & IFN-γ) and proinflammatory cytokines by immune cells from 
humans, mice and some domestic animals (Hemmi et al., 2000; Hornung et al., 2002; Krieg, 
2002; Mutwiri et al., 2003; Wattrang et al., 2005; Hoene et al., 2006; Booth et al., 2007; Dar et 
al., 2008). These proinflammatory cytokines include IL-1, IL-6, IL-8, IL-12, IL-18 and TNF-α. 
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Although no agreement on optimal activation of innate immunity by CpG-DNA through TLR9 
has been reached, synthetic immunostimulatory CpG-oligodeoxynucleotides (ODNs) have been 
widely tested for their activation of innate immunity and adjuvant activity for immunization 
when applied as vaccine adjuvants (Krieg, 2006). 
CpG-DNA has showed superior adjuvant activity with many vaccine antigens. CpG-
DNA as an adjuvant promotes antigen specific CTLs and Th1 CMI as well as Th1-specific 
humoral response in murine (Tighe et al., 2000; Welters et al., 2007; Malherbe et al., 2008). 
Such immune responses are crucial for mammalian hosts to effectively clear viral and other 
intracellular pathogens. 
The biggest challenge for CpG-DNA to be applied as an effective vaccine adjuvant in 
domestic animals is its species specificity. To overcome such an obstacle, all species of CpG-
DNA have to be tested in domestic animals to determine their potential as effective vaccine 
adjuvants (Rankin et al., 2001; Mutwiri et al., 2003). However, there is no universally accepted 
system for such a test in vivo or in vitro. One question that remains to be answered is what are 
the biomarkers for the activation of innate immunity by CpG-DNA. Type I IFNs and IFN-
inducible protein-10 (IP-10/CXCL10) can be considered as the putative biomarkers for CpG-
DNA activation of innate immunity (Krieg, 2002; Klinman et al., 2004; Vicari et al., 2007). IFNs 
have demonstrated remarkable antiviral and antitumor properties as well as having a role in 
bridging innate and adaptive immunity (Blackwell and Krieg, 2003; Pashenkov et al., 2006; 
Averett et al., 2007; Thomas et al., 2007; Cooper et al., 2008; Stewart et al., 2008). One potential 
concern with pronounced induction of immune responses comes from the inflammatory 
properties of TNF-α and other cytokines. TNF-α stimulation in immune cells may be associated 
with septic shock (Tracey and Cerami, 1994; Heikenwalder et al., 2004; von Beust et al., 2005; 
Wang et al., 2007). 
As in other mammals, equine TLR9 is mainly expressed intracellularly in all immune 
cells, including PMNs, T and B cells, monocytes and DCs (Hornung et al., 2002; Flaminio et al., 
2007; Zhang et al., 2008). In innate immunity, PMNs play an essential role in the first line of 
defense against pathogenic infection and tissue damage (Nathan, 2006). PMNs express PRRs to 
sense microbial pathogen-associated molecular patterns (PAMPs). Appropriate PRR-PAMP 
interaction, either through direct contact with or via phagocytosis of pathogen and infected host 
cells may culminate in PMN activation. Recruitment of PMNs to infected or damaged tissue can 
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initiate a cascade of PMN activation, which further results in recruitment/migration and 
activation of immature DCs and other immune cells. Thus, PMNs play an essential role in the 
orchestration of host immune responses (van Gisbergen et al., 2005; Nathan, 2006). However, 
CpG-DNA stimulation of equine PMNs has not been reported in domestic animals, including 
horses. 
CpG-ODNs 2216 and D19 demonstrated some antiviral activity in an indirect bioassay of 
IFNs that were induced in equine PBMCs (Wattrang et al., 2005). In vitro stimulation by CpG-
ODN 2216 on mRNA expression of type I IFNs and IL-12 in PBMCs from two horses was also 
reported (Wattrang et al., 2005). Potential but non-significant stimulation by CpG-ODN 2135 on 
mRNA expression of IFN-α and IL-12 in equine moDCs using quantitative RT-PCR was 
demonstrated (Flaminio et al., 2007). CpG ODN 2007 was tested as an adjuvant in equine 
influenza virus vaccine and showed improved humoral immune response when compared with 
conventional vaccine alone (Lopez et al., 2006). Overall, there is a paucity of published data 
demonstrating CpG-DNA can significantly stimulate equine innate immune response. Whether 
CpG-DNA can stimulate secretion of IFNs, IL-1β, IL-4, IL-6, IL-8, IL-12, IL-18 and TNF-
α from PBMCs, DCs and/or PMNs remains to be demonstrated and is paramount to know prior 
to in vivo testing CpG-DNA as a vaccine adjuvant. 
To study equine innate immune responses to CpG-DNA in horses, though arguably 
through TLR9 signaling pathway, equine PMNs, PBMCs and moDCs were stimulated 
respectively with CpG-ODNs 2006, 2395 and two other CpG-ODNs we designed. 
Characterization of immune activation was determined by cytokine expression using quantitative 
one-step RT-PCR. Our data showed that CpG-DNA significantly stimulated IL-8 and TNF-α 
production in equine PMNs, enhanced expression of IFN-α, IFN-β, IFN-γ, IL-6, IL-8 and IL-
12p35 in PBMCs as well as IFN-α and IFN-γ in moDCs. These tested CpG-DNA species 
showed antiviral and antitumor properties due to their activation of IFN expression in immune 
cells. They also showed potential as vaccine adjuvants to enhance CTLs and Th1 CMI against 
intracellular pathogens because of their apparent induction of type I IFNs and Th1-specific 
cytokines such as IL-12p35 and IFN-γ. 
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 2. Materials and Methods 
 
2.1. Animals and blood sampling 
All animal protocols were approved by the Institutional Animal Care and Use Committee 
at Kansas State University. Peripheral blood samples (50 ml or less) were collected by jugular 
venipuncture using heparinzed syringes from randomly-selected healthy Quarter horses and 
Quarter horse type breeds, 12-25 years of age. 
 
2.2. PBMCs, PMNs isolation and moDCs differentiation 
Equine PMNs and PBMCs were isolated by density-gradient separation using 
Histopaque®-1083 (Sigma-Aldrich, St. Louis, MO) as described (Zhang et al., 2008). To obtain 
equine moDCs, monocytes were purified from PBMCs by plastic adherence, then were cultured 
for 5-6 days with recombinant human granulocyte/macrophage colony stimulating factor (GM-
CSF) and recombinant equine IL-4 (R&D Systems, Minneapolis, MN), each at 10 ng/ml/106 
cells (Hammond et al., 1999). Culture media was partly replaced with fresh media with GM-CSF 
and IL-4 every 2-3 days. 
 
2.3. CpG-ODN design and synthesis 
Bacterial genomic DNA has many unmethylated CpG motifs and can stimulate innate 
immune responses though the TLR9 pathway (Hemmi et al., 2000; Bauer et al., 2001; Dalpke et 
al., 2006). We also analyzed genomic DNA CpG frequency in these bacteria describe by Dalplke 
et al. and a Rhodococcus equi virulence plasmid (GenBank accession no. AF116907 or 
AM947677). Rhodococcus equi is a facultative intracellular bacterium causing fatal 
bronchopneumonia in foals. Compared to other bacteria like Mycobacterium tuberculosis and E. 
coli, this Rhodococcus equi virulence plasmid has the highest frequency of CpG and could have 
potential as a vaccine adjuvant through the TLR9 signaling pathway. We extracted two DNA 
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sequences, designated as RP1 and RP2, with most CpG motifs from this plasmid. The RP1’s 
sequence is TCCCGTCGTTACGCGCTTCCTCGCGTT and RP2’s sequence is 
CTCGCGTCGTTCATCCTGTCGTTCGTG. CpG-ODNs RP1 and RP2 as well as 2006 ( 
TCGTCGTTTTGTCGTTTTGTCGTT) and 2395 (TCGTCGTTTTCGGCGCGCGCCG) 
(Vollmer et al., 2004) were synthesized and purified by Integrated DNA Technologies 
(Coralville, IA). All the bases except the last one of these CpG-ODNs were phosphorothioated. 
CpG-ODN purity was confirmed by mass spectrometry data. 
 
2.4. Cell culture and CpG-DNA stimulation 
Complete media for cell culture consisted of RPMI 1640, 10% FBS and 1% penicillin-
streptomycin (Hyclone, Logan, UT). Freshly isolated equine PMNs (4 x 106/ml) were cultured 
with or without designed CpG-ODNs (2 μM) for 4 hr before harvest for total RNA isolation. 
Freshly isolated PBMCs (4 x 106/ml) were cultured with or without designated CpG-ODNs (2 
μM) for 10 and 24 hr before harvest for total RNA isolation. Following differentiation for 5 to 6 
days in complete media with recombinant human GM-CSF and recombinant equine IL-4, 
moDCs (1 x 106/ml) were treated in the presence or absence of CpG-ODNs (2 μM) for 4 and 15 
hr before harvest for total RNA isolation. The stimulation time and CpG-ODN concentration for 
PMNs (Jozsef et al., 2006) and PBMCs (Marshall et al., 2003) were optimized for activation of 
innate immunity, so was the CpG-ODN concentration. Inactivated/killed West Nile virus 
(KWNV) was purified from West Nile Innovator® vaccine (Fort Dodge Animal Health Inc., Fort 
Dodge, IA) by ultracentrifugation (20,000g for 1 hr at 4 oC). KWNV (120 ug/ml) was utilized to 
stimulate PMNs and PBMCs and to determine the effect of KWNV on equine innate immunity 
in vitro. This treatment also was used to compare antiviral activity between KWNV and CpG-
DNA. 
 
2.5. Quantitative RT-PCR 
Total RNA was isolated from immune cells using an RNeasy Mini Kit (Qiagen, Valencia, 
CA). Quantitative one-step RT-PCR was performed on DNase I-digested total RNA samples 
using the QuantiFast SYBR Green RT-PCR Kit (Qiagen Inc, Valencia, CA) in a Bio-Rad iCycler 
iQ Real Time PCR System (Bio-Rad, Hercules, CA). 
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Quantitative RT-PCR for 18S rRNA (as the internal control for our experiments) and 
cytokine expression was performed in 15-ul reactions with 15 ng total RNA and gene-specific 
primers (Table 3.1). The specificity of all primer pairs was confirmed by sequencing amplicon if 
unique product was amplified based on its electrophoresis in 1-2% agarose gel, as well as 
melting-curve analysis in real time RT-PCR. Negative controls without total RNA were included 
for each run of real time RT-PCR. The PCR amplification efficiency of each reaction was 
estimated by linear regression, in which 3 to 6 points covering the Ct value were utilized based 
on the highest correlation coefficiency (Ramakers et al., 2003). The averaged PCR efficiency for 
each gene was determined for relative gene expression study (Pfaffl, 2001; Cikos et al., 2007). 
 
2.6. Statistical analyses 
All mRNA expression data were normalized to 18S rRNA and relative fold change in 
gene expression was calculated in comparison with control (media/no stimulation). Paired t-test 
for normally distributed data set or Mann-Whitney Rank Sum Test on ranks in SigmaStat 3.5 
was performed for all data analyses. p < 0.05 is considered statistically significant. Since most of 
our data were not normally distributed, box-and-whisker plots in Sigmaplot 10 (Systat Software, 
Inc., San Jose, CA) were applied to show the data, in which error-like bars at the top and bottom 
are the 95th and 5th percentiles, respectively; the bottom and top of the box are always the 25th 
and 75th percentiles, respectively. Some extremely high or low data points were plotted as 
outliers by the box-and-whisker plot program, however, these data points were consistently from 
the same horses, relatively independent of CpG-DNA stimulation. 
 
 
3. Results 
 
3.1. Induction of proinflammatory cytokines by CpG-DNA in PMNs 
TLR9 is expressed in human and equine PMNs (Fransson et al., 2007; Zhang et al., 
2008), thus bacterial DNA and CpG-ODN can activate PMNs through TLR9-dependent 
signaling pathway even though TLR9-independent pathways may exist (El Kebir et al., 2008; 
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Fuxman Bass et al., 2008). In our study, purified equine PMNs were stimulated respectively with 
CpG-ODN 2006, 2395, RP1, RP2 and KWNV for 4 hr (about half of PMN’s half life), 
minimizing the impact of PMN apoptosis during longer time of challenge. After challenge, the 
expression of IL-1β, IL-6, IL-8 and TNF-α in PMNs were measured by quantitative RT-PCR. 
Compared to control (media alone), all the tested CpG-ODNs showed significantly (p = 0.002) 
strong stimulation of IL-8 expression in PMNs by 1 to more than 3,000 fold increase (Fig. 3.1). 
KWNV failed to induce IL-8 expression in PMNs. The variation in PMN’s IL-8 expression 
mainly came from the different responses to CpG-ODN among horses. CpG-ODNs 2006, 2395 
and RP2 also showed significant induction of TNF-α expression in PMNs, but this response was 
weaker than that of IL-8. None of the challenge conditions induced any significant change in 
expression IL-1β and IL-6 in PMNs (Fig. 3.1). 
 
3.2. Induction of IFNs and proinflammatory cytokines by CpG-DNA in PBMCs 
IFNs play a crucial role in host defense against viral infections and neoplasia. In addition, 
these proteins play a role in bridging innate and adaptive immunity because IFN-α/β promotes 
antigen cross-presentation by DCs (Whitmire et al., 2005; Havenar-Daughton et al., 2006; 
Borden et al., 2007; Sadler and Williams, 2008). Another beneficial feature of IFNs is their anti-
inflammatory function (Kovarik et al., 2008). Thus, stimulation of IFNs by CpG-DNA in 
immune cells is of great importance in the evaluation of adjuvant activities of CpG-DNA 
(Klinman et al., 2004; Krieg, 2007).  
In this study, equine PBMCs were stimulated for 10 and 24 hr with CpG-ODNs 2006, 
2395, RP1 and RP2 and KWNV to determine induction of IFNs and proinflammatory cytokines. 
Compared to control, all the CpG-ODNs stimulated significant (p = 0.002) expression of IFN-α, 
IFN-β and IFN-γ at 10 and/or 24 hr stimulation. CpG-ODN 2006 and 2395 induced relatively 
more IFN-γ expression than CpG-ODNs RP1 and RP2. KWNV induced significant (p = 0.002) 
IFN-α and IFN-γ at both 10 and 24 hr stimulation, but at a lower magnitude when compared to 
CpG-ODNs (Fig. 3.2). 
Among proinflammatory cytokines, induction of Th1 cytokine IL-12 by CpG-ODN in 
PBMCs was measured as expression of its unique subunit IL-12p35 instead of IL-12p40 because 
IL-12p40 is also a subunit of Th17 cytokine IL-23 (Oppmann et al., 2000; Weaver et al., 2007; 
 61
Tesmer et al., 2008). Compared to control, IL-12p35 expression was enhanced significantly (p = 
0.002) at 10 hr stimulation by all the 4 CpG-ODNs and at 24 hr stimulation by CpG-ODNs 2006 
and 2395 (Fig.3). The higher IL-12p35 stimulation by CpG-ODNs 2006 and 2395 was consistent 
with correspondingly higher IFN-γ induction in Fig. 3.2 when compared with CpG-ODNs RP1 
and RP2 because Th1 cytokine IL-12 specifically induces IFN-γ expression in NK and T cells 
(Trinchieri, 2003; Kovarik et al., 2008). 
The expression of proinflammatory cytokine IL-6 was induced significantly in PBMCs at 
both 10 and 24 hr stimulation by CpG-ODN 2006, at 24 hr stimulation by CpG-ODNs 2395, RP1 
and RP2 as well as KWNV when compared to control. KWNV induced relative lower IL-6 
expression than these CpG-ODNs (Fig. 3.3). Compared to control, IL-8 expression was induced 
significantly (p = 0.002) at 10 and 24 hr stimulation by all the CpG-ODNs as well as KWNV, 
indicating the activation status of immune cells. Interestingly, IL-18 expression was significantly 
(p = 0.002) suppressed in PBMCs by KWNV and CpG-ODN 2006 at 10 hr stimulation when 
compared to control, other than this, no change in IL-18 expression in PBMCs was identified. 
Compared to control, the expression of proinflammatory cytokine TNF-α and Th2 cytokine IL-4 
in PBMCs was not affected significantly by either CpG-ODNs or KWNV stimulation (Fig. 3.3). 
  
3.3. Induction of IFN-α/γ in moDCs 
DCs are crucial professional antigen-presenting cells (APCs) that bridge innate and 
adaptive immunity and regulate immunity and tolerance via PRRs such as TLRs (Reis e Sousa, 
2006). Here, equine moDCs were first differentiated with human GM-CSF and recombinant IL-
4, and subsequently stimulated with CpG-ODNs 2006 and 2395. Induction of IFN-α/γ in moDCs 
by CpG-ODNs was investigated. It was found that CpG-ODNs 2006 and 2395 stimulated 
significant IFN-α expression (p ≤ 0.001) at 4 and 15 hr stimulation as well as significant IFN-γ 
expression (p = 0.026) at 15 hr stimulation when compared to control cells (Fig. 3.4). 
 
 
4. Discussion 
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Bacterial DNA or unmethylated CpG-DNA has been researched for a dozen of years for 
its immunostimulatory effect on immune cells in mammals, leading to its application as a Th1-
biased vaccine adjuvant for immunization. Ongoing trials of CpG-ODNs are being carried on in 
mice, humans and domestic animals. In domestic animals, few in vivo and in vitro host immune 
responses to CpG-DNA were investigated. In porcine lymph nodes and PBMCs, ex- vivo CpG-
ODNs can induce significant production of Th1 cytokines IFNs and IL-12 (Booth et al., 2007). 
Such host innate immune response to CpG-DNA appears to be essential prior to its application as 
an effective vaccine adjuvant. 
In vitro activation of neutrophils by CpG-DNA has not been previously reported for 
domestic animals, including horses. In our study, we found that CpG-ODNs 2006 and 2395 and 
those from Rhodococcus equi virulence plasmid activated equine PMNs based upon the 
expression of IL-8 and TNF-α in PMNs (Fig. 3.1). That some horses consistently showed high 
up to 3000-fold change in IL-8 mRNA induction by CpG-ODNs probably is because of the 
autocrine effect of chemokine IL-8 and TLR9-dependent/independent pathways for PMNs’ 
activation by bacterial CpG-DNA (Alvarez et al., 2006; Jozsef et al., 2006). The impact of CpG-
ODNs on induction of equine IL-8 protein in PMNs may also need investigation. 
PMN activation provided the basis for the migration and activation of immature DCs and 
other immune cells. Whether all bacterial DNA or other CpG-ODNs activates PMNs from horses 
or other domestic animals the similar way, through TLR9 signaling pathway, remains to be 
determined. The lack of significant induction of IL-1β and IL-6 by CpG-ODNs in PMNs was 
due to low response to CpG-DNA stimulation in two horses at the sampling time. Variability 
among individuals may prevent us from observing their synchronous peak innate immune 
response to CpG-DNA challenge, using either PMNs, or PBMCs, or moDC, or other immune 
cell subsets. Some data points appeared to be outliers in the box-and-whisker plots (Fig. 3.1 to 
3.4), but they were consistently from the same horses under any CpG-ODN stimulation. The 
box-and-whisker plots demonstrated great variation among individuals. 
Regardless of the variation in equine innate immune responses to CpG-DNA among 
individuals, significant induction of type I IFNs, IFN-γ and IL-12 by CpG-ODNs (2006, 2395, 
RP1 and RP2) was observed in equine PBMCs in our investigation. In addition, IL-6 and IL-8, 
but not IL-18 and IL-4 demonstrated an increased expression (Fig. 3.2 & 3.3). The reason why 
KWNV and CpG-ODN 2395 suppressed IL-18 expression in PBMCs after 10 hr stimulation is 
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unknown. However, this is distinct from the IL-18 stimulation in human PBMCs by the Th2-
CMI-promoting Alum adjuvant plus lipopolysaccharide (LPS) (Li et al., 2007), which yet needs 
proving in horses. 
Plasmacytoid DCs are particularly important in host defense against viral infection due to 
their capability of sensing viral nuclei acids and subsequent IFN production (Gilliet et al., 2008). 
Due to lack of immunological reagents for purification or differentiation of equine plasmacytoid 
DCs, moDCs using plastic adherence have been a good alternative for studying equine DC 
immune function (Hammond et al., 1999), even though the purity of moDCs and control of 
maturation is problematic. In our study, significant induction of IFN-α and IFN-γ by CpG-ODNs 
2006 and 2395 was observed in equine moDCs (Fig. 3.4), indicating these CpG-ODNs’ good 
adjuvant properties. However, significant induction of IL-12-p35 in moDCs was not observed in 
our challenge with CpG-ODNs (data not shown). An optimal time to measure peak IL-12p35 
expression in moDCs when stimulated with CpG-ODNs may have been missed in our 
experiment, suggesting further investigation is needed. 
In general, the biomarkers for equine innate immunity activation by CpG-DNA appeared 
to be IL-8, IFN-α, IFN-β, and IFN-γ, there was no reason for us to rule out not monitoring the 
induction of proinflammatory cytokines such as IL-12, IL-1β, IL-6 and TNF-α. Proinflammatory 
cytokines may exist in the host like a double-edged sword: low level induction of 
proinflammatory cytokines is essential for effective host immune response, however, high level 
expression may be deleterious to the host (Tracey and Cerami, 1994; Mann, 2003; Moller and 
Villiger, 2006; Taqueti et al., 2006; Fogal and Hewett, 2008). We did not observe Th2 cytokine 
IL-4 stimulation by CpG-ODN in our experiment. In addition, Th17 immune response is found 
to be highly associated with autoimmune diseases and possibly involved in asthma and allergic 
diseases (Weaver et al., 2007; Tesmer et al., 2008). Whether CpG-DNA stimulates expression of 
equine Th17 cytokines such as IL-17 and IL-23 in equine immune cells remains to be determined 
even though such stimulation was not observed in human (Kattah et al., 2008). 
When compared to the relative weaker induction of Th1 cytokines in equine immune 
cells by KWNV and possibly other vaccine antigens that were not tested here, these tested CpG-
ODNs can induce stronger activation of immune cells and a more pronounced Th1-biased innate 
immunity, thus could promote CTLs and Th1-biased adaptive immunity if applied as vaccine 
adjuvants. Furthermore, the enhanced expression of IFNs in innate immune cells due to CpG-
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DNA not only is crucial for host viral clearance, but also may play an importance role in 
mediating host immune responses due to their anti-inflammatory functions against possibly 
exuberant proinflammatory cytokines such as IL-1β and TNF-α (Borden et al., 2007; Kovarik et 
al., 2008). These data provide a legitimate reason for investigation of these CpG-ODNs as 
potentially effective vaccine adjuvants in horses. 
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Table 3.1 Primers designed for quantitative RT-PCR. 
Gene Primer Sequence (5' to 3') Amplicon 
Length (bp) 
GenBank 
accession No. 
18S rRNA Forward ATGCGGCGGCGTTATTCC 204 AJ311673 
 Reverse GCTATCAATCTGTCAATCCTGTCC     
IFN-α Forward CGGAAGCCTCAAGCCATCTC 225 M14540, M14542, 
 Reverse GTATCTCCTCACAGCCAGCAG  M14543, M14544 
IFN-β Forward TGAGCAAGCACAGCAGTTCC 160 A33685 
 Reverse GCCAAGTTCCTGAGCATTTCC   
IFN-γ Forward GCCAAATCGTCTCCTTCTACTTC 260 D28520 
 Reverse CTGACTCCTCTTCCGCTTCC   
IL-1β Forward AAGGAGAAGAAGAGACTGAC 238 U92481 
 Reverse GCTTGAGAGGTGCTGATG   
IL-4 Forward GAACAACCTCACAGATGGAAAG 238 AF305617 
 Reverse GCTCTTCTTGGCTTCATTCAC   
IL-6 Forward AAGATGAAGAATCCAGAAGTAACC 219 U64794 
 Reverse CTGACCAGAGGAAGGAATGC   
IL-8 Forward GCCTTGGTTTCTTCTTTAATC 253 AY184956 
 Reverse CACTCTAACATCATTACATTATCC   
IL-12p35 Forward GAGGACCGTCAGCAACAC 233 Y11130  
 Reverse ACAGCGTCATCATAGAAGAGG   
IL-18 Forward TCAGATTACTTTGGCAGGCTTG 212 Y11131 
 Reverse TCACACTTCACAGAGATGGTTAC   
TNF-α Forward TTGTGCCTCAGCCTCTTC 109 AB035735 
 Reverse CATTCGGTAACTGCTCTTCC   
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Fig. 3.1. Relative fold changes in expression of IL-8, TNF-α, IL-1β and IL-6 in equine  
PMNs due to stimulation by KWNV and CpG-ODNs 2006, 2395, RP1 and RP2 when 
compared to control (media). Freshly isolated PMNs were cultured for 4 hr in complete 
medium at 4 x 106 cells/ml, in the presence or absence of KWNV and CpG-ODNs. The cytokine 
gene expression was measured by one-step quantitative RT-PCR, using 18S rRNA as the internal 
control for mRNA data normalization. The relative gene expression as fold change was 
calculated in comparison with control (n=6). The control’s relative gene expression was 1 and of 
no fold change. The stars indicated a statistically significant difference (p = 0.002) between 
control and stimulation. The dashed thick blue bar is for the mean, the thin black bar for the 
median. In the box-and-whisker plot, some data points appeared to be outliers (black dots), but 
they were consistently shown from the same horses under any CpG-ODN stimulation. The box-
and-whisker plot, regardless of statistical distribution, just showed great variation among 
individuals (same for the rest of figures). 
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Fig. 3.2. Relative fold changes in expression of IFN-α, IFN-β and IFN-γ in equine PBMCs  
due to stimulation by KWNV and CpG-ODNs 2006, 2395, RP1 and RP2 when compared to 
control (n=6). Freshly isolated PBMCs were cultured for 10 hr and 24 hr in complete medium at 
4 x 106 cells/ml, in the presence or absence of KWNV and CpG-ODNs. The mRNA expression 
of IFNs was analyzed as in Fig. 3.1. The control’s relative gene expression was 1 and of no fold 
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change. The stars indicated a statistically significant difference (p = 0.002) between control and 
stimulation. The dashed thick blue bar is the mean, the thin black bar is the median. 
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                         10 hr stimulation                                             24 hr stimulation 
 
Fig. 3.3. Relative fold changes in expression of proinflammatory cytokines IL12p35, IL-6,  
IL-8, IL-18, TNF-α and IL-4 in equine PBMCs due to stimulation by KWNV and CpG-
ODNs 2006, 2395, RP1 and RP2 when compared to control (n=6). Total RNA was from the 
same samples as in Fig. 3.2. The mRNA expression of proinflammatory cytokines was analyzed 
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as in Fig. 3.1. The control’s relative gene expression was 1 and of no fold change. The stars 
indicated a statistically significant difference (p = 0.002) between control and stimulation. The 
dashed thick blue bar is the mean, the thin black bar is the median. 
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                            4 hr stimulation                                               15 hr stimulation 
Fig. 3.4. Relative fold changes in expression of IFN-α and IFN-γ in equine moDCs due to  
stimulation by CpG-ODNs 2006 and 2395 when compared to control (n=7). Equine moDCs 
were differentiated with recombinant human GM-CSF and recombinant equine IL-4 from 
monocytes. The differentiated equine moDCs were cultured for 4 hr and 15 hr in complete 
medium at 1 x 106 cells/ml, in the presence or absence of CpG-ODNs. The mRNA expression of 
IFNs was analyzed as in Fig. 3.1. The control’s relative gene expression was 1 and of no fold 
change (not shown in the box and whisker plots). The stars indicated a statistically significant 
difference (p ≤ 0.001 for IFN-α, p = 0.026 for IFN-γ at 15 hr,) between control and stimulation. 
The dashed thick blue bar is for the mean, the thin black bar for the median.  
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Abstract  
 
Quantitative reverse transcription polymerase chain reaction (RT-PCR) has become a basic, 
reliable and sensitive modern technique, in both biological research and clinical diagnosis, for 
investigation of gene expression and validation of cDNA microarray analysis. Accurate mRNA 
quantification using quantitative RT-PCR commonly requires data normalization through stable 
housekeeping genes (HKGs). Selection of HKGs for data normalization is critical for accurate 
mRNA quantification. Our objective was to evaluate a set of candidate HKGs as internal controls 
for gene expression studies using quantitative RT-PCR in equine tissues and cell culture. One-
step quantitative RT-PCR for 6 HKGs was performed using total RNA from horse tissues and 
cultured peripheral blood mononuclear cells (PBMCs). The stability of HKGs was mainly 
evaluated by analysis of variance, analyses of the standard deviation and coefficient of variation 
of Ct, and change of Ct of HKGs between control and treated samples. 18S rRNA consistently 
showed the smallest standard deviation and coefficient of variation, and the least change of Ct 
between control and treated samples, thus was the most stable HKG for mRNA data 
normalization in quantitative RT-PCR for studying gene expression in equine tissues and 
cultured PBMCs. 
Key words: Equine, housekeeping gene, quantitative RT-PCR, normalization 
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1. Introduction 
Quantitative RT-PCR has become a reliable and sensitive contemporary approach for 
investigation of gene expression (Bustin, 2000; Bustin, 2002; Pusterla, Madigan et al., 2006; 
Draghici, Khatri et al., 2006; Draghici, Khatri et al., 2006). It can be performed in a one-step or 
two-step procedure. In two-step RT-PCR, the RT and PCR steps are carried out in the separate 
reactions with random hexamers, oligo(dT)  or gene-specific primers for RT and gene-specific 
primers for PCR. In one-step RT-PCR, the RT and PCR steps are carried out in the same reaction 
with gene-specific primers. Compared to two-step RT-PCR, one-step RT-PCR has less chance 
for contamination and may provide higher sensitivity with optimized reaction (Wacker & 
Godard, 2005; Peters, Helps et al., 2004).  In real-time PCR, gene expression can be monitored 
through fluorescence labeled gene-specific TaqMan probes or similar probes in a monoplex or 
multiplex reaction, or through SYBR Green I (a double-stranded DNA binding dye for monoplex 
reactions) with a melting-curve analysis to confirm the specificity of PCR reaction (Gomes-Ruiz, 
Nascimento et al., 2006; Bustin, 2000; Bustin, 2002). SYBR Green I has an economical 
advantage over TaqMan probes. In a monoplex reaction, both SYBR Green I and TaqMan probe-
based real-time PCR assays are equivalent in sensitivity and specificity. 
Quantitative RT-PCR data can be analyzed using an absolute standard curve method or 
relatively quantification method (Livak & Schmittgen, 2001; Pfaffl, 2001; Bustin, 2000). 
Absolute quantification determines the exact transcription copy number based on calibrated 
standard curves, which are labor intensive and time consuming. Relative quantification is often 
preferred because it only requires threshold cycle (Ct) numbers and estimated PCR amplification 
efficiencies of both target and housekeeping gene (HKG) in control and treated samples. The 
relative fold change of gene expression is usually normalized through a HKG in case of minor 
difference exists in starting amount of RNA, RNA quality, RT and PCR amplification 
efficiencies. The accurate estimation of PCR amplification efficiency also has a tremendous 
impact on mRNA quantification (Cikos, Bukovska et al., 2007). Thus, the challenge for accurate 
relative mRNA quantification through real-time RT-PCR is to find a stable HKG for data 
normalization.  
The criteria for selecting a HKG for data normalization include that the HKG’s mRNA 
expression is stable and minimally regulated under any experiment condition. However, there is 
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no universal HKG reported that can be applied for normalization of gene expression under all 
conditions. Thus, it is essential to find one or two best HKGs that are appropriate for data 
normalization under certain experimental conditions. Among the most commonly used HKGs are 
18S rRNA (18S), Beta-actin (B-actin), glyceraldehyde-3-phosphate dehydrogenase (GAPDH), 
and hypoxanthine ribosyl transferase 1 (HPRT1).  
In equine, there was no reported research on internal controls for studying gene 
expression in tissues and cultured cells using quantitative RT-PCR, except one involving only 
equine sarcoids (Bogaert, Van et al., 2006). Our objective was to apply some simple but 
unbiased statistical methods to evaluate a set of candidate HKGs as internal controls for gene 
expression studies in equine tissues and cell culture using SYBR Green I-based one-step 
quantitative RT-PCR. 
 
 
2. Materials and Methods 
 
2.1.  Tissue sampling, cell culture and RNA isolation 
All animal protocols were approved by the Institutional Animal Care and Use Committee 
at Kansas State University. Horse tissues were collected immediately postmortem from three 
euthanized adult Quarter Horses. Tissue samples for RNA isolation were snap frozen in liquid 
nitrogen and stored at -80 oC for further total RNA isolation. Samples collected included colon, 
heart, kidney, liver, lung, lymph node, small intestine and spleen. Whole blood samples were 
collected from 6 healthy, adult horses that were 3-25 years of age and appropriately vaccinated 
annually against West Nile virus (WNV). PBMCs from 6 adult Quarter Horses were isolated as 
previously reported by density gradient (Zhang, Davis et al., 2008).  PBMCs (1 x 106/ml) were 
cultured in complete media (Zhang, Davis et al., 2008) at 37 oC, with or without purified WNV 
antigen (pre-membrane plus envelope proteins, 20 ug/ml, Fort Dodge Animal Health, Fort 
Dodge, IA) for 3-4 days before harvest for RNA extraction. Total RNA from tissue samples and 
cultured PBMCs was isolated and quantified as reported (Zhang, Davis et al., 2008). The total 
RNA quality was confirmed using RNA 6000 Nano Assay Kit (Agilent Technologies, Santa 
Clara, CA). 
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 2.2. Quantitative RT-PCR 
Primers for HKGs including 18S, 28S rRNA (28S), Beta2-microglobulin (B2M), B-actin, 
GAPDH and HPRT1 were designed using Beacon Designer 4.0 (PREMIER Biosoft 
International, Palo Alto, CA) for SYBR Green I assay (Table A.1). The specificity of each 
primer pair was confirmed by sequencing amplicon if unique product was amplified based on 
electrophoresis in 1-2% agarose gel, as well as melting-curve analysis in real time RT-PCR. 
One-step quantitative RT-PCR was performed in duplicate on DNase I-treated total RNA 
samples from individual animals using a QuantiFast SYBR Green RT-PCR Kit (Qiagen Inc, 
Valencia, CA). In a Bio-Rad iCycler iQ Real Time PCR System (Bio-Rad, Hercules, CA), 
quantitative RT-PCR for these HKGs was performed in 15 ul reaction with 15 ng of total RNA 
and 0.6 uM final primer concentration for each forward and reverse primer. The RT-PCR 
protocol was 1 min annealing at the melting temperature of the reverse primer to ensure the 
specificity of RT reaction, 10 min RT reaction at 50 oC, 5 min PCR activation at 95 oC, then 40 
cycles of 10 sec denaturation at 95 oC, 15 sec annealing at the lower of primer pair’s melting 
temperature and 10 to 20 sec (depending on the length of amplicon) PCR extension at 72 oC, and 
finally a melting-curve analysis for confirming the RT-PCR specificity. Negative controls, 
without RT or total RNA, were included in each run of RT-PCR. Ct was automatically 
determined by the Optical System Software (Version 3.1) with the Bio-Rad iCycler iQ Real 
Time PCR System. The PCR amplification efficiency of each reaction was estimated by linear 
regression, in which 3 to 6 points covering the Ct value were utilized based on the highest 
correlation coefficiency (Ramakers, Ruijter et al., 2003). 
 
2.3. Statistical Analyses 
The data of each biological sample’s duplicates were averaged. The Ct values, the key 
products of quantitative RT-PCR that have a negative correlation with the logarithm of 
transcription copy number of targeted genes, are crucial for accurate mRNA quantification. 
Thus, the stability of HKGs was mainly evaluated by analyzing the standard deviation and 
coefficient of variation of Ct, and change of Ct between control and treated samples. 
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Expression data were normalized as reported, using averaged amplification efficiencies 
of target and internal control genes (Pfaffl, 2001). 
One way and two way analysis of variance or Kruskal-Wallis one way analysis of 
variance on ranks were performed in SigmaStat 3.5, with p-value less than 0.05 as significant. 
All pairwise multiple comparisons were performed with Holm-Sidak method. 
 
 
3. Results and Discussion 
 
Based the criteria for HKGs, we analyzed Ct values of 18S, 28S, B2M, B-actin, GAPDH 
and HPRT1 among horse tissues and cultured PBMCs. Among colon, heart, kidney, liver, lung, 
lymph node, small intestine and spleen, no significant difference was observed for 18S, 28S, B-
actin, GAPDH and HPRT1 (Fig. A. 1). However, there was statistically significant (p = 0.001) 
difference in B2M between heart and colon, liver, lymph node, small intestine or spleen, thus 
B2M is the least stable HKG for normalization of tissue mRNA data. The significant higher Ct in 
B2M in the heart than colon, liver, lymph node, small intestine and spleen suggests a lower 
expression of major histocompatibility complex (MHC) class I antigens. This is consistent with 
what was observed in normal healthy cardiac tissue unless inflammation occurs due to disease or 
heart transplantation rejection in humans (Zavazava, Bottcher et al., 1993; Hengstenberg, 
Hufnagel et al., 1993). 
WNV antigen stimulates substantial in vitro antigen-specific CD4 & CD8 T cell 
proliferation due to vaccination and/or natural exposure to WNV in adult horses (data not 
shown). The expression of 18S, 28S, B2M, B-actin, GAPDH and HPRT1 was investigated in 
PBMCs cultured with or without purified WNV antigen. No significant difference in Ct of these 
6 HKGs between control and stimulated PBMCs was observed (Fig. A. 2). For cultured PBMCs, 
the expected ΔCt (difference in Ct of a HKG between control and stimulated PBMCs) should be 
near 0, indicating a good stability of the HKG (Pfaffl, 2001). However, the data (Fig. A. 2) 
showed none of the 6 HKGs met the expectation even though equal amount of total RNA was 
applied for each RT-PCR reaction, indicating possible uneven efficiencies in RT and/or PCR 
steps. 
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Among tissues or cultured PBMCs, no statistically significant difference observed in 
HKGs’ Ct does not decisively indicate these HKGs are equivalent for mRNA data normalization. 
In cultured PBMCs, the ΔCt (difference in Ct between control and stimulated PBMCs) was 
analyzed (Fig. A. 2). 18S and 28S showed the least change in Ct between control and stimulated 
PBMCs, suggesting they might be the appropriate HKGs for mRNA data normalization. We 
further analyzed the Ct values across all tissues and between cell culture conditions. Compared 
to the other 5 HKGs, 18S consistently showed the smallest standard deviation and coefficient of 
variation even though 18S had the lowest Ct values (Table A.2). These results demonstrated that 
18S is the most stable HKG in quantitative RT-PCR for mRNA data normalization. 
PCR amplification efficiencies of the 6 HKGs for all quantitative RT-PCR reactions were 
estimated by a linear regression method (Ramakers, Ruijter et al., 2003). These estimates were 
very high and also showed high consistency or stability across samples (106.46% ± 5.61% (mean 
± standard deviation) for 18S, 120.17% ± 9.68%  for 28S, 100.00% ± 8.57% for B2M, 99.24% ± 
9.13% for B-actin, 103.31% ± 7.88% for GAPDH and 99.47 % ± 10.16% for HPRT1). No 
statistically significant difference was observed in PCR amplification efficiencies of the 6 HKGs 
across all tissues and between cell culture conditions. 
The mRNA data from quantitative RT-PCR are normalized to HKGs to justify minor 
differences in starting amount of RNA, RNA quality, RT and PCR amplification efficiencies, 
thus accurate relative gene expression data could be obtained. However, there is no universal 
HKG found as a stable internal control for mRNA data normalization. Although researchers have 
spent a tremendous amount of effort to develop a reasonable method to search stable HKGs or 
complicated algorithm for normalizing mRNA data from quantitative RT-PCR, there is no 
perfect method that has been reported. A recent report regarding validation of candidate bovine 
reference genes with real-time PCR applied three computer programs (BestKeeper, NormFinder 
and geNorm) that unanimously identified B-actin and GAPDH as the most appropriate HKGs in 
blood for data normalization (Robinson, Sutherland et al., 2007). Interestingly, this could simply 
be achieved when the standard deviation and coefficient of variation of HKGs’ Ct values were 
ranked. Such a simple but practical method appeared to have enough power for the search of 
stable HKGs for data normalization. Thus we applied this efficient simple method for our study 
and identified that 18S is the most appropriate HKG in quantitative RT-PCR for mRNA data 
normalization in equine tissues and cultured PBMCs. 
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As shown in our experiment, 18S is the most suitable HKG for mRNA expression 
normalization because it shows the highest stability as a HKG. However, many HKGs after 
stimulation (Fig. A. 2) or 18S in tumor cells (Tricarico, Pinzani et al., 2002) might be slightly 
upregulated. Thus, to find a suitable HKG for mRNA expression normalization appeared to be 
essential for every experimental condition. 
Many factors could contribute to the variation in HKGs’ Ct estimates. In our experiment, 
no significant correlation between Ct and PCR amplification efficiencies was observed for 18S, 
B2M, B-actin, GAPDH and HPRT1, indicating that PCR amplification efficiency was not a 
factor contributing the Ct variation of these 5 HKGs. Sample variation could contribute most 
even though equal amount total RNA was applied. Other factors like the relative uncertainty of 
DNA amplification due to inherent stochastic kinetics of RT-PCR reaction (Peccoud & Jacob, 
1996), the operators and time could also account for the variation of Ct estimates (Bustin, 2002). 
Such artificially and systemically introduced variation in Ct estimates in quantitative RT-PCR is 
thus exponentially amplified after data normalization in relative quantification of mRNA. This 
brings up two questions: i) Can we solve the circular problem of finding a stable HKG for data 
normalization even though there appears to be no reliable method to evaluate the stability of 
candidate HKGs? (Andersen, Jensen et al., 2004); ii) Which data, Ct or normalized mRNA data, 
should be analyzed? There is no doubt that real time or quantitative RT-PCR is an accurate and 
highly sensitive modern technique in mRNA quantification. However, it requires highly 
specialized expertise and techniques to ensure the accuracy and precision of data acquisition and 
thus better opportunity to find a reliable HKG for data normalization. Analysis of Ct data for the 
determination of HKGs’ stability under experimental conditions is nonetheless a good approach 
and independent of the targeted genes. For targeted genes, the analysis of variance in normalized 
mRNA data instead of Ct data of target genes statistically requires more biological replicates to 
ensure significant results due to the exponential amplification of artificially and systemically 
introduced variation. If no reliable HKG for data normalization can be identified, Ct-based 
analysis of relative target gene expression is a good choice as long as total RNA for each RT-
PCR reaction is equally loaded, the quantitative RT-PCR reactions for each target or reference 
gene are performed simultaneously and the result presents meaningful biological significance. 
The relative fold change in gene expression can be computed by (1+E)ΔCt, where E is the average 
PCR amplification efficiency of the target gene. This approach is equivalent as considering ΔCt 
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of the reference HKG as 0 (Pfaffl, 2001). It can also be considered as normalizing the target gene 
expression to equally loaded total RNA. Equal loading of total RNA in quantitative RT-PCR is 
the foundation of evaluating internal controls’ stability. This approach has an advantage of 
avoiding the introduction of external variation in mRNA quantification due to normalization 
against a possibly fallible HKG, but has a disadvantage of not justifying the unavoidable error 
from the measurement of sample RNA concentration. 
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Table A.1. Housekeeping gene primers for quantitative RT-PCR 
Gene GenBank 
accession No. 
Forward Primer (5'~3') Reverse Primer (5'~3') Amplicon 
Length (bp) 
18S AJ311673 ATGCGGCGGCGTTATTCC GCTATCAATCTGTCAATCCTGTCC 204 
28S EU554425 CGGGTAAACGGCGGGAGTAAC TAGGTAGGGACAGTGGGAATCTCG  109 
B-actin AF035774 CACCACACCTTCTACAAC ATCTGGGTCATCTTCTCG  107 
B2M X69083 GGCTACTCTCCCTGACTGG ACACGGCAACTATACTCATCC  271 
GAPDH AF157626 GCCATCACCATCTTCCAG GACTCCACAACATATTCAGC  77 
HPRT1 AY372182 GAGATGTGATGAAGGAGATG TGACCAAGGAAAGCAAGG  300 
  
 
Table A.2. Descriptive statistics of threshold cycles (Ct) of 6 housekeeping genes in horse 
tissues and cultured PBMCs, where PBMCs were cultured for 3 days, with or without 
stimulation of West Nile virus antigen before being harvest for total RNA isolation. Stdev is for 
standard deviation of Ct. CV is for coefficient of variation. 
 
Gene Tissues (n=24)  Cell culture (n=12)  
 Ct Mean Stdev CV Ct Mean Stdev CV 
18S 11.9 0.43 3.56% 11.6 0.49 4.20% 
28S 10.1 0.55 5.46% 9.8 0.62 6.30% 
B2M 18.5 1.62 8.73% 15.4 0.73 4.75% 
B-actin 15.5 0.73 4.73% 16.4 1.08 6.63% 
GAPDH 18.8 0.82 4.38% 18.7 0.84 4.53% 
HPRT1 24.4 1.41 5.78% 22.0 0.79 3.61% 
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Fig. A.1. Comparison of threshold cycle (Ct) of 6 housekeeping genes for quantitative RT-
PCR among 8 horse tissues. Pairwise comparison showed statistically significant difference in 
B2M between heart and any of colon, liver, lymph node, small intestine and spleen. The error bar 
shows 95% confidence interval.  
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Fig. A.2. Relative expression of 6 housekeeping genes in PBMCs after culture for 3 days, 
with or without stimulation of West Nile virus antigen. Delta Ct is the Ct difference between 
control and stimulated PBMCs.  
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